US20170165482A1 - Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa - Google Patents
Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa Download PDFInfo
- Publication number
- US20170165482A1 US20170165482A1 US15/373,698 US201615373698A US2017165482A1 US 20170165482 A1 US20170165482 A1 US 20170165482A1 US 201615373698 A US201615373698 A US 201615373698A US 2017165482 A1 US2017165482 A1 US 2017165482A1
- Authority
- US
- United States
- Prior art keywords
- neurostimulator
- delivery tool
- stimulation lead
- hub portion
- double barrel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000598 pterygopalatine fossa Anatomy 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 28
- 230000000638 stimulation Effects 0.000 claims abstract description 71
- 230000004936 stimulating effect Effects 0.000 claims abstract description 10
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 8
- 208000005400 Synovial Cyst Diseases 0.000 claims description 8
- 238000004891 communication Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 description 51
- 231100000869 headache Toxicity 0.000 description 48
- 239000004033 plastic Substances 0.000 description 19
- 229920003023 plastic Polymers 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 208000019695 Migraine disease Diseases 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 229910052751 metal Inorganic materials 0.000 description 15
- 239000002184 metal Substances 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229910001092 metal group alloy Inorganic materials 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 238000002513 implantation Methods 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 208000006561 Cluster Headache Diseases 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 210000003484 anatomy Anatomy 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- 229910001220 stainless steel Inorganic materials 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 206010027599 migraine Diseases 0.000 description 7
- 230000002889 sympathetic effect Effects 0.000 description 7
- 230000002567 autonomic effect Effects 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 210000002050 maxilla Anatomy 0.000 description 6
- 208000004296 neuralgia Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000000060 Migraine with aura Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000001375 Facial Neuralgia Diseases 0.000 description 4
- 206010016059 Facial pain Diseases 0.000 description 4
- 208000018238 Primary Headache disease Diseases 0.000 description 4
- 208000008548 Tension-Type Headache Diseases 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 208000018912 cluster headache syndrome Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000002820 sympathetic nervous system Anatomy 0.000 description 4
- 210000001738 temporomandibular joint Anatomy 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010027603 Migraine headaches Diseases 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- 206010028836 Neck pain Diseases 0.000 description 3
- 206010054874 Sphenopalatine neuralgia Diseases 0.000 description 3
- 206010043269 Tension headache Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001667 episodic effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000001734 parasympathetic effect Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- 208000026533 urinary bladder disease Diseases 0.000 description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- 206010003791 Aura Diseases 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 206010051550 Carotidynia Diseases 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 208000032106 Complicated migraine Diseases 0.000 description 2
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 2
- 229910001200 Ferrotitanium Inorganic materials 0.000 description 2
- 208000004095 Hemifacial Spasm Diseases 0.000 description 2
- 206010019476 Hemiplegic migraine Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000582005 Homo sapiens Neuron navigator 3 Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102100030464 Neuron navigator 3 Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010068106 Occipital neuralgia Diseases 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 206010036313 Post-traumatic headache Diseases 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 208000017143 Secondary Headache disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 208000007777 paroxysmal Hemicrania Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 208000030062 persistent idiopathic facial pain Diseases 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004357 third molar Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000003116 Adie Syndrome Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000031108 Chronic hiccup Diseases 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000019530 Eagle syndrome Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000005922 Glossalgia Diseases 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- 206010020352 Holmes-Adie pupil Diseases 0.000 description 1
- 208000016297 Holmes-Adie syndrome Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023848 Laryngeal pain Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241001272720 Medialuna californiensis Species 0.000 description 1
- 206010072720 Medication overuse headache Diseases 0.000 description 1
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005538 Post-Dural Puncture Headache Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000007077 SUNCT syndrome Diseases 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 208000004557 Vasovagal Syncope Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940000031 blood and blood forming organ drug Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001326 carotid sinus Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000000033 corpus adiposum buccae Anatomy 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 208000024874 headache associated with sexual activity Diseases 0.000 description 1
- 208000020727 hemicrania continua Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000011529 hypnic headache Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000017420 migraine with brainstem aura Diseases 0.000 description 1
- 206010052787 migraine without aura Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 210000005034 parasympathetic neuron Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3468—Trocars; Puncturing needles for implanting or removing devices, e.g. prostheses, implants, seeds, wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
- A61N1/36075—Headache or migraine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37205—Microstimulators, e.g. implantable through a cannula
Definitions
- the present disclosure relates generally to surgical tools configured to deliver medical devices to a craniofacial region of a subject and, more particularly, to surgical tools configured to deliver an implantable neurostimulator to a pterygopalatine fossa of a subject.
- Headaches are one of the most debilitating ailments that afflict millions of individuals worldwide. The specific pathophysiology of headaches is unknown. Known sources of headache pain consist of trauma, vascular, autoimmune, degenerative, infectious, drug and medication-induced, inflammatory, neoplastic, metabolic-endocrine, iatrogenic, musculoskeletal and myofacial causes. Also, even though the possible underlying cause of the headache pain is identified and treated, the headache pain may persist.
- SPG sphenopalatine ganglion
- the SPG is an extracranial neuronal center located behind the nose. It consists of parasympathetic neurons that innervate (in part) the middle cerebral and anterior cerebral blood vessels, the facial blood vessels, and the lacrimal glands.
- the SPG also consists of sympathetic and sensory nerve fibers that pass through the SPG in route to their end organs. Manipulation of the SPG is mostly performed in attempted treatments of severe headaches, such as cluster headaches or migraines.
- the neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes.
- the delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath.
- the hub portion can be located between the shaft and a spine member that extends axially away from the hub portion.
- the hub portion can be sized and dimensioned to releasably mate with the neurostimulator.
- the double barrel sheath can be connected to the spine member.
- a central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.
- the neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes.
- One step of the method can include loading the neurostimulator onto a delivery tool.
- the delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion located between the shaft and a spine member that extends axially away from the hub portion, and a double barrel sheath connected to the spine member. At least a portion of the shaft and the hub portion can include a central lumen extending therethrough.
- the delivery tool can be advanced so that the stimulation lead of the neurostimulator is adjacent a PPF of the subject.
- An ejector lead can then be deployed through the central lumen of the delivery tool to cause the stimulation lead to emerge from the double barrel sheath so that the stimulation lead is in close proximity to the SPG.
- the delivery tool can be withdrawn so that the neurostimulator remains implanted in the subject.
- the neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes.
- the delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion located between the shaft and a trunk member that extends axially away from the hub portion, a spine member connected to and extending from the trunk member, and a double barrel sheath connected to the spine member.
- the neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes.
- One step of the method can include loading the neurostimulator onto a delivery tool.
- the delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion located between the shaft and a trunk member that extends axially away from the hub portion, a spine member connected to and extending from the trunk member, and a double barrel sheath connected to the spine member.
- the tool can be advanced so that the stimulation lead of the neurostimulator is adjacent a PPF of the subject.
- the handle can be manipulated to cause a lead ejector of the delivery tool to displace the stimulation lead from the double barrel sheath so that the stimulation lead is in close proximity to the SPG.
- the delivery tool can then be withdrawn so that the neurostimulator remains implanted in the subject.
- the advancing, manipulating, and withdrawing steps can be performed using a navigation system.
- FIG. 1 is a perspective view showing part of the nervous innervations of the anterior craniofacial skeleton
- FIG. 2 is a perspective view of an implantable neurostimulator
- FIG. 3 is a schematic illustration of a delivery tool that is configured to deliver an implantable neurostimulator to a pterygopalatine fossa (PPF) of a subject and constructed in accordance with one aspect of the present disclosure;
- PPF pterygopalatine fossa
- FIG. 4 is a perspective view of a handle comprising the delivery tool in FIG. 3 ;
- FIGS. 5A-B are perspective views of an elongated shaft and hub portion comprising the delivery tool in FIG. 3 ;
- FIG. 5C is a cross-sectional view taken along Line 5 C- 5 C in FIG. 5A ;
- FIG. 6 is a perspective view of a spine member comprising the delivery tool in FIG. 3 ;
- FIG. 7A is a perspective view of a double barrel sheath comprising the delivery tool in FIG. 3 ;
- FIG. 7B is a cross-sectional view taken along Line 7 B- 7 B in FIG. 7A ;
- FIG. 8 is a process flow diagram illustrating a method for deploying a neurostimulator in close proximity to a sphenopalatine ganglion (SPG) of a subject according to another aspect of the present disclosure
- FIGS. 9A-C are a series of schematic illustrations showing loading of a neurostimulator onto the delivery tool in FIG. 3 ;
- FIG. 10 is a schematic illustration of a delivery tool that is configured to deliver an implantable neurostimulator to a PPF of a subject and constructed in accordance with one aspect of the present disclosure
- FIGS. 11A-B are perspective views of a handle comprising the delivery tool in FIG. 10 in an assembled configuration ( FIG. 11A ) and an exploded configuration ( FIG. 11B );
- FIGS. 12A-G are a series of schematic illustrations showing an integral lead ejector mechanism of the delivery tool in FIG. 10 ;
- FIGS. 13A-B are perspective views of a hub portion comprising the delivery tool in FIG. 10 ;
- FIG. 13C is a cross-sectional view taken along Line 13 C- 13 C in FIG. 13A ;
- FIG. 14 is a perspective view of a spine member comprising the delivery tool in FIG. 10 ;
- FIG. 15A is a perspective view of a double barrel sheath comprising the delivery tool in FIG. 10 ;
- FIG. 15B is a cross-sectional view taken along Line 15 B- 15 B in FIG. 15A ;
- FIG. 15C is a perspective view of the spine member in FIG. 14 mated with the double barrel sheath ( FIGS. 15A-C );
- FIG. 16 is a process flow diagram illustrating a method for deploying a neurostimulator in close proximity to a SPG of a subject according to another aspect of the present disclosure.
- FIGS. 17A-D are a series of schematic illustrations showing loading and deployment of a neurostimulator from the delivery tool in FIG. 10 .
- the present disclosure relates generally to surgical tools configured to deliver medical devices to a craniofacial region of a subject, and more particularly to surgical tools configured to deliver an implantable neurostimulator to a pterygopalatine fossa (PPF) of a subject.
- the delivery tools of the present disclosure are configured to deliver a neurostimulator into a craniofacial region of a subject, such as the PPF.
- the present disclosure may be employed to assist in treating a variety of chronic or acute medical conditions.
- Examples of such medical conditions can include, but are not limited to, pain (e.g., headache, facial pain, trigeminal neuralgias, sphenopalatine neuralgias and/or atypical face pain), movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, neurological disorders, urinary bladder disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders.
- pain e.g., headache, facial pain, trigeminal neuralgias, sphenopalatine neuralgias and/or atypical face pain
- movement disorders e.g., epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, neurological disorders, urinary bladder disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders.
- phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y.
- phrases such as “between about X and Y” can mean “between about X and about Y.”
- phrases such as “from about X to Y” can mean “from about X to about Y.”
- spatially relative terms such as “under,” “below,” “lower,” “over,” “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms can encompass different orientations of the apparatus in use or operation in addition to the orientation depicted in the figures. For example, if the apparatus in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features.
- headache can refer to migraines, tension headaches, cluster headaches, trigeminal neuralgia, sphenopalatine neuralgia, secondary headaches, tension-type headaches, chronic and episodic headaches, medication overuse/rebound headaches, chronic paroxysmal hemicrinia headaches, hemicranias continua headaches, post-traumatic headaches, post-herpetic headaches, vascular headaches, reflex sympathetic dystrophy-related headaches, cervicalgia headaches, caroidynia headaches, sciatica headaches, trigeminal headaches, occipital headaches, maxillary headaches, chary headaches, paratrigeminal headaches, petrosal headaches, Sluder's headache, vidian headaches, low cerebrospinal fluid pressure headaches, temporomandibular joint (TMJ) headaches, causalgia headaches, myofascial headaches, all primary headaches (e.g., primary stabbing headache
- cluster headache can refer to extremely painful and debilitating headaches that occur in groups or clusters.
- Cluster headaches can include chronic or episodic cluster headaches, cluster-type headaches, histamine headaches, histamine cephalalgia, Raedar's syndrome and sphenopalatine neuralgia.
- migraine can refer to an intense and disabling chronic or episodic headache typically characterized by severe pain in one or both sides of the head.
- Migraines can include, but are not limited to, migraine without aura, migraine with aura, migraine with aura but without headache, menstrual migraines, variant migraines, transformed migraines, menstrual migraine, complicated migraines, hemiplegic migraines, atypical migraines, chronic migraines, basilar-type migraines, childhood periodic syndromes that are commonly precursors of migraine (e.g., abdominal, cyclic vomiting, BPV, etc.), status migrainous, and all types of probable migraines.
- facial pain can refer to direct pain that typically involves nerves supplying the face or, alternatively, indirect (referred) pain from other structures in the head, e.g., blood vessels.
- the pain may be related to headache (e.g., migraine), muscular syndromes (e.g., TMJ), and herpetic or rheumatic disease or injury.
- the terms “modulate” or “modulating” can refer to causing a change in neuronal activity, chemistry and/or metabolism.
- the change can refer to an increase, decrease, or even a change in a pattern of neuronal activity.
- the terms may refer to either excitatory or inhibitory stimulation, or a combination thereof, and may be at least electrical, biological, magnetic, optical or chemical, or a combination of two or more of these.
- the terms can also be used to refer to a masking, altering, overriding, or restoring of neuronal activity.
- close proximity with reference to a portion of an electrode or electrical lead relative to a target nerve structure (e.g., sphenopalatine ganglia or SPG) can refer to a distance between the electrode (or electrical lead) and the target nerve structure sufficient to enable electrical modulation of the target nerve structure.
- “close proximity” can refer to a distance between the electrode (or electrical lead) and the target nerve structure whereby the electrode (or electrical lead) is not in direct contact with the nerve structure, but electrical modulation of the target nerve structure is still possible.
- “close proximity” can mean that the distance between an electrode or electrical lead and a target nerve structure is less than 1 mm but direct contact between structures does not occur.
- “close proximity” can mean that the distance between an electrode or electrical lead and a target nerve structure is greater than 1 mm (e.g., about 1 mm to about 1 cm), but direct contact between structures does not occur.
- the term “subject” can refer to any warm-blooded organism including, but not limited to, human beings, pigs, rats, mice, dogs, goats, sheep, horses, monkeys, apes, rabbits, cattle, etc.
- prevent shall have its plain and ordinary meaning to one skilled in the art of pharmaceutical or medical sciences.
- prevent can mean to stop or hinder a medical condition, such as a headache.
- treat or “treating” shall have their plain and ordinary meaning to one skilled in the art of pharmaceutical or medical sciences.
- “treat” or “treating” can mean to prevent or reduce a medical condition, such as a headache.
- the term “medical condition” can refer to pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, urinary bladder disorders, abnormal metabolic states, disorders of the muscular system, infectious and parasitic diseases, neoplasms, endocrine diseases, nutritional and metabolic diseases, immunological diseases, diseases of the blood and blood-forming organs, mental disorders, diseases of the nervous system, diseases of the sense organs, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the genitourinary system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, congenital anomalies, certain conditions originating in the perinatal period, and symptoms, signs, and ill-defined conditions.
- Pain treatable by the present invention can be caused by conditions including, but not limited to, migraine headaches, including migraine headaches with aura, migraine headaches without aura, menstrual migraines, migraine variants, atypical migraines, complicated migraines, hemiplegic migraines, transformed migraines, and chronic daily migraines, episodic tension headaches, chronic tension headaches, analgesic rebound headaches, episodic cluster headaches, chronic cluster headaches, cluster variants, chronic paroxysmal hemicranias, hemicrania continua, post-traumatic headache, post-traumatic neck pain, post-herpetic neuralgia involving the head or face, pain from spine fracture secondary to osteoporosis, arthritis pain in the spine, headache related to cerebrovascular disease and stroke, headache due to a vascular disorder, reflex sympathetic dystrophy, cervicalgia (which may be due to various causes including, but not limited to, muscular, discogenic or degenerative, including arthritic, posturally related or metastatic), glossodynia, carotidynia,
- Movement disorders treatable by the present invention may be caused by conditions including, but not limited to, Parkinson's disease, cerebropalsy, dystonia, essential tremor and hemifacial spasms.
- Epilepsy treatable by the present invention may be, for example, generalized or partial.
- Cerebrovascular disease treatable by the present invention may be caused by conditions including, but not limited to, aneurysms, strokes, and cerebral hemorrhage.
- Autoimmune diseases treatable by the present invention include, but are not limited to, multiple sclerosis.
- Sleep disorders treatable by the present invention may be caused by conditions including, but not limited to, circadian rhythm disorders, sleep apnea and parasomnias.
- Autonomic disorders treatable by the present invention may be caused by conditions including, but not limited to, gastrointestinal disorders, including but not limited to gastrointestinal motility disorders, nausea, vomiting, diarrhea, chronic hiccups, gastroesphageal reflux disease, and hypersecretion of gastric acid, autonomic insufficiency, autonomic instability, excessive epiphoresis, excessive rhinorrhea, and cardiovascular disorders including, but not limited, to cardiac dysrythmias and arrythmias, hypertension, carotid sinus disease, Holmes-adie syndrome, orthostatic hypotension, striatonigral degeneration, vasovagal syncope, lyme disease and autonomic instability.
- gastrointestinal disorders including but not limited to gastrointestinal motility disorders, nausea, vomiting, diarrhea, chronic hiccups, gastroesphageal reflux disease, and hypersecretion of gastric acid, autonomic insufficiency, autonomic instability, excessive epiphoresis, excessive rhinorrhea, and cardiovascular disorders including, but not
- Neurological disorders treatable by the inventive method may be caused by conditions including, but not limited to: hemifacial spasm, Melkersson-Rosenthal Syndrome and Parry-Romberg syndrome.
- Urinary bladder disorders treatable by the present invention may be caused by conditions including, but not limited to, spastic or flaccid bladder.
- Abnormal metabolic states treatable by the present invention may be caused by conditions including, but not limited to, hyperthyroidism or hypothyroidism.
- disorders of the muscular system treatable by the present invention can include, but are not limited to, muscular dystrophy, and spasms of the upper respiratory tract and face.
- Neuropsychiatric or mental disorders treatable by the present invention may be caused by conditions including, but not limited to, depression, schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
- the autonomic nervous system innervates numerous pathways within the human body and consists of two divisions: the sympathetic and the parasympathetic nervous systems.
- the sympathetic and parasympathetic nervous systems are antagonistic in their action, balancing the other system's effects within the body.
- the sympathetic nervous system (SNS) usually initiates activity within the body, preparing the body for action, while the parasympathetic nervous system (PNS) primarily counteracts the effects of the SNS.
- the SPG 10 ( FIG. 1 ) are located on both sides of the head. It shall be assumed for the following discussion of the present invention that reference is being made to the SPG 10 located on the left side of the head.
- the SPG 10 is part of the parasympathetic division of the autonomic nervous system; however, the SPG has both sympathetic and parasympathetic nerve fibers, as well as sensory and motor nerve fibers either synapsing within the ganglion (e.g., parasympathetic) or fibers that are passing through the ganglion and not synapsing (e.g., sympathetic, sensory and motor).
- the parasympathetic activity of the SPG 10 is mediated through the greater petrosal nerve (not shown), while the sympathetic activity of the SPG is mediated through the deep petrosal nerve (not shown), which is essentially an extension of the cervical sympathetic chain (not shown).
- Sensory sensations generated by or transmitted through the SPG 10 include, but are not limited to, sensations to the upper teeth, feelings of foreign bodies in the throat, and persistent itching of the ear.
- the SPG 10 transmits sensory information, including pain, to the trigeminal system via the maxillary division (not shown).
- One aspect of the present disclosure includes a delivery tool 16 ( FIG. 3 ) configured to deliver a neurostimulator into a craniofacial region of a subject.
- the neurostimulator can be configured for implantation in the PPF 14 .
- the neurostimulator is sized and configured for implantation on a posterior maxilla 12 .
- a neurostimulator capable of being delivered by the delivery tool 16 can generally include any active implantable medical device configured to deliver electrical stimulation, alone or in combination with other types of stimulation to tissue of a subject.
- the neurostimulator can further include any active implantable medical device configured for implantation for a relatively short period of time (e.g., to address acute medical conditions) or a relatively long period of time (e.g., to address chronic medical conditions). Additionally, the neurostimulator can include one or more elements used to record or monitor a physiological response of a subject's tissue (e.g., a delivered therapy), as well as one or more other components that interface with the patient's tissue (e.g., therapeutic agent delivery mechanisms, sensors, etc.).
- a subject's tissue e.g., a delivered therapy
- other components that interface with the patient's tissue e.g., therapeutic agent delivery mechanisms, sensors, etc.
- a neurostimulator 18 can be configured as shown in FIG. 2 and disclosed in U.S. Pat. No. 8,494,641 to Boling et al. (hereinafter, “the '641 patent”), the entirety of which is hereby incorporated by reference.
- the neurostimulator 18 can comprise a stimulator body 20 , an integral stimulation lead 22 , which includes one or more stimulating electrodes 24 , and an integral fixation apparatus 26 .
- the neurostimulator 18 can be implanted as disclosed in the '641 patent, i.e., such that the stimulator body 20 is positioned sub-periosteally medial to the zygoma 28 ( FIG.
- the integral fixation apparatus 26 ( FIG. 2 ) is anchored to the zygomaticomaxillary buttress 30 ( FIG. 1 ) such that the integral stimulation lead 22 ( FIG. 2 ) is placed within the PPF 14 ( FIG. 1 ) or, more specifically, in close proximity (e.g., about 1-5 mm) to the SPG 10 .
- the delivery tool 16 ( FIG. 3 ) of the present disclosure is designed and configured to facilitate delivery of a neurostimulator in close proximity to the SPG 10 ( FIG. 1 ) so that targeted electrical stimulation or delivery of electrical current from the neurostimulator to the SPG can be accomplished.
- the delivery tool 16 can comprise a handle 32 , an elongated shaft 34 extending from the handle, a hub portion 36 located between the shaft and a spine member 38 , and a double barrel sheath 40 connected to the spine member.
- the delivery tool 16 is designed and configured to be inserted trans-orally from an incision located on the posterior maxilla 12 ( FIG. 1 ).
- the delivery tool 16 ( FIG. 3 ) can have a length L of about 10 cm to about 30 cm. In one example, the delivery tool 16 can have a length L of about 14 cm. All or only a portion of the delivery tool 16 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as titanium or stainless steel, medical grade plastics (e.g., PEEK, polycarbonate, nylon), glass, ceramics (e.g., aluminum, zirconium oxide), combinations of metals, ceramics, plastics or plastic composites, and the like.
- medical grade metal or metal alloy such as titanium or stainless steel, medical grade plastics (e.g., PEEK, polycarbonate, nylon), glass, ceramics (e.g., aluminum, zirconium oxide), combinations of metals, ceramics, plastics or plastic composites, and the like.
- the handle 32 can be ergonomically formed and have a length of about 6 cm to about 12 cm.
- the handle 32 can vary in diameter from a proximal end 42 (e.g., about 0.5 cm to about 3 cm) to a distal end 44 (e.g., about 0.5 cm to about 2 cm) thereof.
- the handle 32 can include various features to provide grip and tactile maneuverability, such as circumferential ridges or a cross-hatched precut pattern (not shown) into the material forming the handle. As shown in FIG.
- the handle 32 can include a series of radially spaced apart depressions 46 (e.g., three) to provide a user with not only grip and tactile maneuverability, but also a visual cue to assist with proper positioning and orientation of the neurostimulator 18 during delivery.
- the handle 32 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, and the like.
- the elongated shaft 34 ( FIGS. 5A-C ) of the delivery tool 16 includes oppositely disposed first and second end portions 48 and 50 .
- the first end portion 48 is sized and dimensioned for insertion into a channel 52 of the handle 32 .
- the second end portion 50 is securely connected to, or integrally formed with, the hub portion 36 of the delivery tool 16 .
- the elongated shaft 34 can have any desired length and diameter. In some instances, the length of the elongated shaft 34 can be about 3 cm to about 7 cm. In one example, the length of the elongated shaft 34 can be about 4.5 cm. The diameter of the elongated shaft 34 can be about 0.1 cm to about 1 cm.
- the diameter of the elongated shaft 34 can be about 0.3 cm. In some instances, the diameter of the elongated shaft 34 can be uniform between the first and second end portions 48 and 50 . In other instances, the diameter of the elongated shaft 34 can taper from the first end portion 48 to the second end portion 50 (or vice-versa).
- the elongated shaft 34 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like.
- the elongated shaft 34 also includes an opening or slot 54 .
- the slot 54 can be located about any portion of the elongated shaft 34 . In one example, the slot 54 is located at or about the middle of the elongated shaft 34 . Although the slot 54 is shown in FIGS. 5A-C as having a rectangular shape, it will be appreciated that the slot can have any desired shape (e.g., circular, square, ovoid, etc.).
- the slot 54 forms part of a central lumen 56 ( FIG. 5C ), which extends through the elongated shaft 34 from the slot, through the second end portion 50 , and through the hub portion 36 . As described in more detail below, the slot 54 (and the central lumen 56 ) is adapted to receive an ejector lead 58 ( FIGS. 9A-C ) therethrough.
- the hub portion 36 ( FIGS. 5A-C ) is located between the elongated shaft 34 and the spine member 38 .
- the hub portion 36 is sized and configured to releasably mate with a neurostimulator 18 .
- the hub portion 36 comprises a port 60 configured to slidably receive a stimulator body 20 of the neurostimulator 18 .
- the port 60 is defined by a lower surface 62 , which is integrally formed with oppositely disposed side walls 64 , as well as an upper portion 66 that includes a plurality of tangs 68 .
- the upper portion 66 can include only one tang 68 .
- the hub portion 36 thus includes a second opening 70 that is in fluid communication with the central lumen 56 .
- the second opening 70 can be shaped like a bowling pin such that a first portion 72 thereof is adapted to receive the spine member 38 , and a second portion 74 thereof is adapted to receive the double barrel sheath 40 .
- the hub portion 36 can further include one or more channels 76 that extend from the lower surface 62 into the central lumen 56 .
- the channel(s) 76 are sized and dimensioned to receive a fastener (not shown), such as a dowel to connect the spine member 38 to the hub portion 36 .
- the hub portion 36 can include two channels 76 of identical diameter and length, each of which is adapted to receive a dowel.
- the lower surface 62 can be sized and dimensioned to allow the hub portion 36 to releasably mate with the neurostimulator 18 .
- the lower surface 62 can have a length of about 0.5 cm to about 2 cm (e.g., about 1 cm).
- the lower surface 62 can have a width of about 0.5 cm to about 2 cm (e.g., about 1 cm).
- Each of the oppositely disposed side walls 64 can have any desired height, such as about 0.1 cm to about 0.5 cm (e.g., about 0.3 cm). As shown in FIG. 5A , each of the side walls 64 can have a contoured arcuate portion 78 .
- the tangs 68 in addition to the lower surface 62 and the side walls 64 are configured to provide a retention force when the stimulator body 20 is received in the port 60 .
- Each of the tangs 68 includes an overhang portion 80 for contacting a portion of the stimulator body 20 (e.g., when the neurostimulator 18 is disposed in the port 60 ).
- Each of the overhang portions 80 permits the amount of a retention force between the stimulator body 20 and the hub portion 36 to be selectively adjusted. For example, bending of the integral fixation apparatus 26 of the neurostimulator 18 towards a surface 82 of the upper portion 66 creates opposing forces between the overhang portions 80 and a surface of the stimulator body 20 . Increasing an adjustment angle of the integral fixation apparatus 26 towards the surface 82 results in an increased retention force. Removal of the retention force during retraction requires the integral fixation apparatus 26 to be pushed away from the surface 82 .
- the hub portion 36 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like.
- the hub portion 36 is configured to hold or carry the neurostimulator body 20 during placement of the neurostimulator 18 .
- the amount of material used to form the hub portion 36 should be minimized to reduce the amount of tissue dissection needed to place the neurostimulator 18 in vivo, as well as to reduce the amount of drag that occurs during placement and removal of the delivery tool 16 .
- the spine member 38 ( FIG. 6 ) extends axially away from, and is securely connected to, the hub portion 36 .
- the spine member 38 has an elongated configuration and includes a proximal end portion 84 , a distal end portion 86 , and an intermediate portion 88 extending between the proximal and distal end portions.
- the proximal end portion 84 is adapted for connection to the hub portion 36 via one or more channel(s) 90 , which is/are configured to receive a fastener, such as a dowel.
- the proximal end portion 84 can include two channels 90 of an identical diameter and length, each of which is adapted to receive a dowel.
- the spine member 38 can have any desired length and width.
- the spine member 38 can have a length of about 4 cm to about 6 cm (e.g., about 5 cm).
- the spine member 38 can have a width of about 0.1 cm to about 0.8 cm (e.g., about 0.3 cm).
- the spine member 38 can have a uniform width or, alternatively, the width of the spine member can taper from a first width at the proximal end portion 84 that is greater than a second width at the distal end portion 86 .
- a distal tip 92 of the spine member 38 can include a tapered arcuate end. In other instances, the distal tip 92 can be bulbous or mushroom-shaped.
- the spine member 38 can have a square-shaped cross-sectional profile; however, it will be appreciated that other cross-sectional profiles are possible (e.g., semi-circular, circular, rectangular, etc.).
- the distal end portion 86 of the spine member 38 can extend at an angle A relative to a longitudinal plane P of the proximal end portion 84 .
- the angle A can be about 10° to about 45°, depending upon the craniofacial anatomy of the subject.
- the spine member 38 can have a rigid, semi-rigid, or flexible configuration.
- the spine member 38 can be made from one or combination of rigid, semi-rigid, or flexible materials, such as metals, metal alloys, and polymers or plastics. In some instances, all or only a portion of the spine member 38 can be malleable. For example, only the distal end portion 86 of the spine member 38 can be malleable. In another example, the spine member 38 can be made of a malleable metal that supports the double barrel sheath 40 and the integral stimulation lead 22 from buckling when longitudinal or lateral forces are encountered.
- the malleability allows a physician to conform the shape of the neurostimulator 18 (e.g., the integral stimulation lead 22 ) to correspond to a patient's anatomy and thereby aid with implantation. Malleability in some cases is not required; thus, a spine member 38 made from a non-malleable material, such as plastic can also serve the intended function.
- the double barrel sheath 40 ( FIGS. 7A-B ) is connected to the spine member 38 .
- the double barrel sheath 40 comprises a first barrel 94 and a second barrel 96 .
- a first lumen 98 and a second lumen 100 extend through the first and second barrels 94 and 96 , respectively.
- the double barrel sheath 40 can have an hour glass-like or figure eight-like cross-sectional profile.
- the first lumen 98 is shaped and dimensioned to receive the spine member 38 . For example, all or only a portion of the spine member 38 can be disposed within the first lumen 98 .
- the spine member 38 is connected to an inner surface (not shown) defining the first lumen 98 by any one or combination of attachment mechanisms, such as adhesives, pins, staples, etc.
- the second lumen 100 is shaped and dimensioned to partially receive the integral stimulation lead 22 of the neurostimulator 18 .
- a first end 102 of the double barrel sheath 40 is securely connected to the second opening 70 of the hub portion 36 such that the central lumen 56 is in fluid communication with the second lumen 100 .
- the double barrel sheath 40 can be securely connected to the hub portion 36 by any one or combination of attachment mechanisms, such as adhesives, pins, staples, etc.
- the double barrel sheath 40 can be made of a semi-flexible material (or materials).
- the double barrel sheath 40 can be formed from a plastic or polymer, such as polytetrafluoroethylene.
- the double barrel sheath 40 can be formed from a flexible material having a thickness of about 0.04 inches to about 0.001 inches.
- the second barrel 96 of the sheath 40 has a splittable configuration to allow for removal or deployment of the integral stimulation lead 22 of the neurostimulator 18 from the sheath with minimal load on the integral stimulation lead.
- a partial section of the second barrel 96 can include a seam 104 adapted to permit egress of the stimulation lead 22 from the second lumen 100 during deployment of the neurostimulator 18 .
- the seam 104 can extend from a second end 106 of the sheath 40 to an opening 108 , which is located at or about the midpoint of the second barrel 96 . In some instances, the distance between the second end 106 and the opening 108 can be equal to, or about equal to, the length of the stimulation lead 22 .
- the seam 104 allows for removal or deployment of the integral stimulation lead 22 of the neurostimulator 18 from the sheath 40 with minimal load on the integral stimulation lead. Undesirable loading on the integral stimulation lead 22 can cause migration of the lead away from the desired implant location during withdrawal of the delivery tool 16 .
- the seam 104 of the sheath 40 is parted during deployment of the neurostimulator 18 , which reduces the load on the integral stimulation lead 22 .
- FIG. 8 Another aspect of the present disclosure is illustrated in FIG. 8 and includes a method 110 for deploying a neurostimulator 18 in close proximity to a SPG 10 of a subject.
- the method 110 can generally include the steps of: loading a neurostimulator 18 onto a delivery tool (Step 112 ); advancing the delivery tool 16 to a PPF 14 (Step 114 ); deploying an ejector lead 58 of the delivery tool (Step 116 ); and withdrawing the delivery tool from the subject (Step 118 ).
- the delivery tool 16 is configured as shown in FIG. 3 and described above
- the neurostimulator 18 is configured as shown in FIG. 2 and described in the '641 patent.
- a delivery path can be surgically formed in the subject as disclosed in U.S. patent application Ser. No. 13/470,480 (hereinafter, “the '480 application”), which is hereby incorporated by reference in its entirety.
- Loading of the neurostimulator 18 onto the delivery tool 16 is illustrated in FIGS. 9A-C . To do so, the neurostimulator 18 is first brought into close proximity with the hub portion 36 of the delivery tool 16 . The neurostimulator 18 is then angled slight downward toward the double barrel sheath 40 of the delivery tool 16 until a distal portion of the integral stimulator lead 22 is introduced or inserted into the opening 108 of the sheath ( FIG. 9A ).
- the neurostimulator 18 is progressively advanced in a distal direction until a portion of the neurostimulator body 20 is in flush contact with the lower surface 62 of the hub portion 36 ( FIG. 9B ). As shown in FIG. 9C , the neurostimulator 18 is then advanced towards the handle 32 of the delivery tool 16 until the neurostimulator body 20 snugly engages the tangs 68 and the integral fixation apparatus 26 engages the surface 82 of the hub portion 36 , thereby providing a retention force to keep the neurostimulator securely mated with the delivery tool during implantation.
- a gingival-buccal insertion site in a similar or identical manner as disclosed in U.S. Patent Publication No. 2010/0185258 A1 (hereinafter, “the '258 application”), which is hereby incorporated by reference in its entirety.
- a #10 scalpel blade (not shown) can be used to make an incision in a horizontal manner between the second and third molars (not shown).
- a first surgical tool (not shown) similar or identical to the one disclosed in the '480 application is inserted into the incision and subperiosteally.
- the anatomy of the subject's skull, including the location and size of the PPF 14 can be determined prior to insertion of the first surgical tool.
- the first surgical tool After inserting the first surgical tool into the incision, the first surgical tool is urged in a posterior direction so that a first major surface of the surgical tool's distal portion traverses under the zygomatic bone 28 along the maxillary tuberosity 120 .
- the first surgical tool is then advanced further until a distal dissecting tip thereof engages the junction formed by the posterior maxillary buttress (not shown) and the pterygoid plate 122 , just inferior and lateral to the PPF 14 . Advancement of the first surgical tool may naturally stop when the distal dissecting tip is correctly positioned at the junction formed by the posterior maxillary buttress and the pterygoid plate 122 .
- the first surgical tool is then withdrawn, thereby creating a surgical access cavity (not shown).
- the delivery tool 16 (with the neurostimulator 18 loaded thereon) can be advanced through the delivery path until the stimulation lead 22 of the neurostimulator is adjacent the PPF 14 (Step 114 ). As shown in FIG. 9A , an ejector lead 58 is then inserted into the slot 54 of the delivery tool 16 .
- the ejector lead 58 can comprise an electrode lead blank configured to have the same or substantially the same dimensions as the integral stimulation lead 22 of the neurostimulator 18 .
- the ejector lead 58 can be progressively advanced through the slot 54 and the central lumen 56 to cause the stimulation lead 22 to emerge from the seam 104 of the double barrel sheath 40 so that the stimulation lead is in close proximity to the SPG 10 .
- the delivery tool 16 can be withdrawn so that the neurostimulator 18 remains implanted in the subject as disclosed in the '641 patent.
- an electrical current from the neurostimulator can be applied to the SPG 10 to treat a medical condition (e.g., headache).
- a navigation-compatible delivery tool 124 is illustrated in FIG. 10 .
- the delivery tool 124 is configured to deliver, with navigation assistance, a neurostimulator into a craniofacial region of a subject.
- navigation systems with which the delivery tool 124 is compatible can include those commercially available from BRAINLAB (Westchester, Ill.), such as the KICK or CURVE systems, the FUSION ENT navigation system (Medtronic, Minneapolis, Minn.), and the NAV3 Navigation Platform (Stryker, Kalamazoo, Mich.).
- the neurostimulator can be configured for implantation in the PPF 14 .
- the neurostimulator is sized and configured for implantation on a posterior maxilla 12 .
- a neurostimulator capable of being delivered by the delivery tool 124 can generally include any active implantable medical device configured to deliver electrical stimulation, alone or in combination with other types of stimulation to tissue of a subject.
- the neurostimulator can further include any active implantable medical device configured for implantation for a relatively short period of time (e.g., to address acute medical conditions) or a relatively long period of time (e.g., to address chronic medical conditions).
- the neurostimulator can include one or more elements used to record or monitor a physiological response of a subject's tissue (e.g., a delivered therapy), as well as one or more other components that interface with the patient's tissue (e.g., therapeutic agent delivery mechanisms, sensors, etc.).
- a neurostimulator 18 is shown in FIG. 2 and described above.
- the delivery tool 124 of the present disclosure is designed and configured to facilitate delivery of a neurostimulator in close proximity to the SPG 10 so that targeted electrical stimulation or delivery of electrical current from the neurostimulator to the SPG can be accomplished.
- the delivery tool 124 can comprise a handle 126 , an elongated shaft 128 extending from the handle, a hub portion 130 located between the shaft and a trunk member 132 that extends axially away from the hub portion, a spine member 134 connected to and extending from the trunk member, and a double barrel sheath 136 connected to the spine member.
- the delivery tool 124 is designed and configured to be inserted trans-orally from an incision located on the posterior maxilla 12 ( FIG. 1 ).
- the delivery tool 124 ( FIG. 10 ) can have a length L of about 10 cm to about 30 cm. In one example, the delivery tool 124 can have a length L of about 14 cm. All or only a portion of the delivery tool 124 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as titanium or stainless steel, medical grade plastics (e.g., PEEK, polycarbonate, nylon), glass, ceramics (e.g., aluminum, zirconium oxide), combinations of metals, ceramics, plastics or plastic composites, and the like.
- medical grade metal or metal alloy such as titanium or stainless steel, medical grade plastics (e.g., PEEK, polycarbonate, nylon), glass, ceramics (e.g., aluminum, zirconium oxide), combinations of metals, ceramics, plastics or plastic composites, and the like.
- the handle 126 ( FIGS. 11A-B ) can be ergonomically shaped and comprise a first component 138 and a second component 140 .
- the handle 126 can have a length of about 6 cm to about 12 cm.
- the handle 126 can vary in diameter from a proximal end 142 (e.g., about 0.5 cm to about 3 cm) to a distal end 144 (e.g., about 0.5 cm to about 2 cm) thereof.
- a first end portion 146 of the first component 138 can include a channel 148 adapted to receive a portion of the second component 140 .
- the first component 138 can include various features to provide grip and tactile maneuverability, such as circumferential ridges or a cross-hatched precut pattern (not shown) into the material forming the handle. As shown in FIGS. 11A-B , the handle 126 can include a series of radially spaced apart depressions 150 (e.g., three) to provide a user with not only grip and tactile maneuverability, but also a visual cue to assist with proper positioning and orientation of the neurostimulator 18 during delivery.
- the first and second components 138 and 140 can be made of the same or different materials, such as a rigid or semi-rigid medical grade metal or metal alloy (e.g., stainless steel), medical grade plastics, polymers, and the like.
- the second component 140 of the handle 126 can have a generally T-shaped configuration that includes a first end portion 152 , a second end portion 154 , and a main body 156 extending between the first and second end portions.
- the first end portion 152 comprises a cap member 158 having a diameter that is greater than a diameter of the main body 156 and the second end portion 154 .
- a lumen 160 that is adapted to receive the elongated shaft 128 extends between the first and second end portions 152 and 154 .
- the main body 156 and the second end portion 154 of the second component 140 can have a tubular or cylindrical shape, and be sized and dimensioned to fit within the channel 148 of the first component 138 .
- annular lip 162 comprising the cap member 158 can directly contact, and be flush with, a first end surface 164 of the first component 138 .
- the second end portion 154 of the second component 140 also includes a step 166 , which, as described in more detail below, forms part of an integral lead ejector mechanism of the delivery tool 124 .
- FIGS. 12A-G illustrate the integral lead ejector mechanism, which comprises the handle 126 , the elongated shaft 128 , a connector component 168 , a plurality of fasteners 170 , and an ejector lead 172 .
- the ejector lead 172 of the delivery tool 124 is an integral component thereof and thereby obviates the need to externally feed an ejector lead into the delivery tool during neurostimulator deployment.
- the integral lead ejector mechanism reduces the time needed to implant a neurostimulator 18 and minimizes the potential for introducing contaminated equipment during a surgical procedure.
- the elongated shaft 128 can extend through the second component 140 of the handle 126 .
- the connector component 168 can be seated on the step 166 of the second component 140 and secured thereto by a plurality of screws 174 .
- a plurality of dowels 176 can extend through the first component 138 of the handle 126 into the elongated shaft to secure the elongated shaft in place.
- the elongated shaft 128 ( FIGS. 12C-D ) includes oppositely disposed first and second end portions 178 and 180 , and a central lumen 182 extending therebetween.
- the second portion 180 of the elongated shaft 128 is sized and dimensioned for insertion into the lumen 160 of the second component 140 of the handle 126 .
- the first end portion 178 is securely connected to, or integrally formed with, the hub portion 130 of the delivery tool 124 .
- the elongated shaft 128 can have any desired length and diameter. In some instances, the length of the elongated shaft 128 can be about 3 cm to about 7 cm. In one example, the length of the elongated shaft 128 can be about 4.5 cm.
- the diameter of the elongated shaft 128 can be about 0.1 cm to about 1 cm. In one example, the diameter of the elongated shaft 128 can be about 0.3 cm. In some instances, the diameter of the elongated shaft 128 can be uniform between the first and second end portions 178 and 180 .
- the elongated shaft 128 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like.
- the elongated shaft 128 also includes an opening or slot 184 .
- the slot 184 can be located about any portion of the elongated shaft 128 . In one example, the slot 184 is located at or about the second end portion 180 of the elongated shaft 128 . Although the slot 184 is shown in FIG. 12C as having a rectangular shape, it will be appreciated that the slot can have any desired shape (e.g., circular, square, ovoid, etc.).
- the slot 184 forms part of the central lumen 182 , which extends through the elongated shaft 128 from the slot, through the first end portion 178 , and through the hub portion 130 . As described in more detail below, the slot 184 (and the central lumen 182 ) is adapted to receive an ejector lead 172 ( FIG. 12G ) therethrough.
- the connector component 168 has a half-moon or semi-circular shape, and includes a plurality of channels 186 extending between first and second major surfaces 188 and 190 thereof. Each of the channels 186 is adapted to receive a fastener (e.g., a screw 174 ) so that the connector component 168 can be secured to the second component 140 of the handle 126 .
- the second major surface 190 includes a groove 192 , which is located between the channels 186 and extends between oppositely disposed first and second edges 194 and 196 of the connector component 168 .
- the groove 192 is adapted to receive an L-shaped portion of the ejector lead 172 .
- the connector component 168 can be formed from one or a combination of materials, such as a medical grade metal or metal alloy, medical grade plastics, polymers, or the like.
- the ejector lead 172 is illustrated in FIG. 12G .
- the ejector lead 172 has a generally L-shaped configuration and includes a first end portion 198 , a second end portion 200 , and a main body portion 202 extending between the first and second end portions.
- Each of the first end portion 198 and the main body portion 202 have an elongated, wire-like shape adapted for insertion into the central lumen 182 of the elongated shaft 128 .
- the second end portion 200 has an L- or elbow-shaped configuration and is adapted to extend through the slot 184 of the elongated shaft 128 .
- the ejector lead 172 functions to displace the stimulation lead 22 of the neurostimulator 18 from the double barrel sheath 136 during operation of the delivery tool 124 .
- the hub portion 130 is located between the elongated shaft 128 and a trunk member 132 .
- the hub portion 130 is sized and configured to releasably mate with a neurostimulator 18 .
- the hub portion 130 comprises a port 204 configured to slidably receive a stimulator body 20 of the neurostimulator 18 .
- the port 204 is defined by a lower surface 206 , which is integrally formed with oppositely disposed side walls 208 , as well as an upper portion 210 that includes a plurality of tangs 212 .
- the upper portion 210 can include only one tang 212 .
- the hub portion 130 thus includes a second opening (not shown) that is in fluid communication with the central lumen 182 .
- the lower surface 206 can be sized and dimensioned to allow the hub portion 130 to releasably mate with the neurostimulator 18 .
- the lower surface 206 can have a length of about 0.5 cm to about 2 cm (e.g., about 1 cm).
- the lower surface 206 can have a width of about 0.5 cm to about 2 cm (e.g., about 1 cm).
- Each of the oppositely disposed side walls 208 can have any desired height, such as about 0.1 cm to about 0.5 cm (e.g., about 0.3 cm). As shown in FIG. 14A , each of the side walls 208 can have a contoured arcuate portion 214 .
- the tangs 212 are configured to provide a retention force when the stimulator body 20 is received in the port 204 .
- Each of the tangs 212 includes an overhang portion 216 for contacting a portion of the stimulator body 20 (e.g., when the neurostimulator 18 is disposed in the port 204 ).
- Each of the overhang portions 216 permits the amount of a retention force between the stimulator body 20 and the hub portion 130 to be selectively adjusted. For example, bending of the integral fixation apparatus 26 of the neurostimulator 18 towards a surface 218 of the upper portion 210 creates opposing forces between the overhang portions 216 and a surface of the stimulator body 20 . Increasing an adjustment angle of the integral fixation apparatus 26 towards the surface 218 results in an increased retention force. Removal of the retention force during retraction requires the integral fixation apparatus 26 to be pushed away from the surface 218 .
- the hub portion 130 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like.
- the hub portion 130 is configured to hold or carry the neurostimulator body 20 during placement of the neurostimulator 18 .
- the amount of material used to form the hub portion 130 should be minimized to reduce the amount of tissue dissection needed to place the neurostimulator 18 in vivo, as well as to reduce the amount of drag that occurs during placement and removal of the delivery tool 124 .
- the trunk member 132 ( FIGS. 13A-C ) is connected to (e.g., integrally formed with) and extends axially away from the hub portion 130 .
- the trunk member 132 has an arcuate, elongated configuration and includes a proximal end portion 220 , a distal end portion 222 , and an intermediate portion 224 extending between the proximal and distal end portions.
- the proximal end portion 220 is connected (e.g., directly connected) to the hub portion 130 .
- the trunk member 132 can have any desired length and width. In one example, the trunk member 132 can have a length of about 4 cm to about 6 cm (e.g., about 5 cm). In another example, the trunk member 132 can have a width of about 0.1 cm to about 0.8 cm (e.g., about 0.3 cm).
- the distal end portion 222 of the trunk member 132 can extend at an angle A ( FIG. 14C ) relative to a longitudinal plane P of the proximal end portion 220 .
- the angle A can be about 10° to about 45°, depending upon the craniofacial anatomy of the subject.
- First and second channels 226 and 228 can extend between the proximal and distal end portions 220 and 222 of the trunk member 132 .
- the first channel 226 can be in fluid communication with the central lumen 182 of the hub portion 130 and the elongated shaft 128 .
- the first channel 226 can have a circular cross-sectional shape.
- the second channel 228 can be sized and dimensioned to receive the spine member 134 .
- the second channel 228 can have a rectangular cross-sectional profile.
- the trunk member 132 can include a channel 230 extending from an upper surface 232 thereof into communication with the second channel 228 .
- the channel 230 is adapted to receive a fastener (e.g., a dowel) for securing the spine member 134 within the second channel 228 .
- a fastener e.g., a dowel
- the spine member 134 extends axially away from, and is securely connected to, the trunk member 132 .
- the spine member 134 has an elongated configuration and includes a proximal end portion 234 , a distal end portion 236 , and an intermediate portion 238 extending between the proximal and distal end portions.
- the proximal end portion 234 is adapted for connection to the trunk member 132 via insertion into the second channel 228 .
- the spine member 134 can be secured in the second channel 228 by a fastener (e.g., a dowel) inserted through the channel 230 of the trunk member 132 .
- a fastener e.g., a dowel
- the spine member 134 can have any desired length and width.
- the spine member 134 can have a length of about 4 cm to about 6 cm (e.g., about 5 cm).
- the spine member 134 can have a width of about 0.1 cm to about 0.8 cm (e.g., about 0.3 cm).
- the spine member 134 can have a uniform width or, alternatively, the width of the spine member can taper from a first width at the proximal end portion 234 that is greater than a second width at the distal end portion 236 .
- a distal tip 240 of the spine member 134 can include a tapered arcuate end. In other instances, the distal tip 240 can be bulbous or mushroom-shaped.
- the spine member 134 can have a square-shaped cross-sectional profile; however, it will be appreciated that other cross-sectional profiles are possible (e.g., semi-circular, circular, rectangular, etc.).
- the distal end portion 236 of the spine member 134 can extend at an angle A relative to a longitudinal plane P of the proximal end portion 234 .
- the angle A can be about 10° to about 45°, depending upon the craniofacial anatomy of the subject.
- the spine member 134 can have a rigid, semi-rigid, or flexible configuration.
- the spine member 134 can be made from one or combination of rigid, semi-rigid, or flexible materials, such as metals, metal alloys, and polymers or plastics. In some instances, all or only a portion of the spine member 134 can be malleable. For example, only the distal end portion 236 of the spine member 134 can be malleable. In another example, the spine member 134 can be made of a malleable metal that supports the double barrel sheath 136 and the integral stimulation lead 22 from buckling when longitudinal or lateral forces are encountered.
- the malleability allows a physician to conform the shape of the neurostimulator 18 (e.g., the integral stimulation lead 22 ) to correspond to a patient's anatomy and thereby aid with implantation. Malleability in some cases is not required; thus, a spine member 134 made from a non-malleable material, such as plastic can also serve the intended function.
- the delivery tool 124 includes a double barrel sheath 136 ( FIGS. 15A-C ) that is connected to the spine member 134 .
- the double barrel sheath 136 comprises a first barrel 242 and a second barrel 244 .
- a first lumen 246 and a second lumen 248 extend through the first and second barrels 242 and 244 , respectively.
- the second lumen 248 can have a rectangular cross-sectional profile and be shaped and dimensioned to receive all or only a portion of the spine member 134 .
- the first lumen 246 can have a circular cross-sectional profile and be shaped and dimensioned to partially receive the integral stimulation lead 22 of the neurostimulator 18 .
- a first end 250 of the double barrel sheath 136 is securely connected to the trunk member 132 so that the central lumen 182 is in fluid communication with the first lumen 246 .
- the double barrel sheath 136 can be securely connected to the trunk member 132 by any one or combination of attachment mechanisms, such as adhesives, pins, staples, etc.
- the double barrel sheath 136 can be made of a semi-flexible material (or materials).
- the double barrel sheath 136 can be formed from a plastic or polymer, such as polytetrafluoroethylene.
- the double barrel sheath 136 can be formed from a flexible material having a thickness of about 0.04 inches to about 0.001 inches.
- the first barrel 242 of the sheath 136 has a splittable configuration to allow for removal or deployment of the integral stimulation lead 22 of the neurostimulator 18 from the sheath with minimal load on the integral stimulation lead.
- a partial section of the first barrel 242 can include a seam 252 adapted to permit egress of the stimulation lead 22 from the first lumen 246 during deployment of the neurostimulator 18 .
- the seam 252 can extend from a second end 254 of the sheath 136 to an opening 256 , which is located at or about the midpoint of the first barrel 242 . In some instances, the distance between the second end 254 and the opening 256 can be equal to, or about equal to, the length of the stimulation lead 22 .
- the seam 252 allows for removal or deployment of the integral stimulation lead 22 of the neurostimulator 18 from the sheath 136 with minimal load on the integral stimulation lead. Undesirable loading on the integral stimulation lead 22 can cause migration of the lead away from the desired implant location during withdrawal of the delivery tool 124 .
- FIG. 16 Another aspect of the present disclosure is illustrated in FIG. 16 and includes a navigation-assisted method 258 for deploying a neurostimulator 18 in close proximity to a SPG 10 of a subject.
- the method 258 can generally include the steps of: loading a neurostimulator 18 onto a delivery tool 124 (Step 260 ); advancing the delivery tool to a PPF 14 (Step 262 ); deploying an integral lead ejector 172 of the delivery tool (Step 264 ); and withdrawing the delivery tool from the subject (Step 266 ).
- the delivery tool 124 is configured as shown in FIG. 10 and described above
- the neurostimulator 18 is configured as shown in FIG. 2 and described in the '641 patent.
- Steps 262 - 266 of the method 258 can be performed using a commercially available navigation system, such as the KICK or CURVE systems (BRAINLAB, Westchester, Ill.), the FUSION ENT navigation system (Medtronic, Minneapolis, Minn.), or the NAV3 Navigation Platform (Stryker, Kalamazoo, Mich.).
- a commercially available navigation system such as the KICK or CURVE systems (BRAINLAB, Westchester, Ill.), the FUSION ENT navigation system (Medtronic, Minneapolis, Minn.), or the NAV3 Navigation Platform (Stryker, Kalamazoo, Mich.).
- a delivery path can be surgically formed in the subject as disclosed in the '480 application.
- Loading of the neurostimulator 18 onto the delivery tool 124 is illustrated in FIGS. 17A-C . To do so, the neurostimulator 18 is first brought into close proximity with the hub portion 130 of the delivery tool 124 . The neurostimulator 18 is then angled slight downward toward the double barrel sheath 136 of the delivery tool 124 until a distal portion of the integral stimulator lead 22 is introduced or inserted into the opening 256 of the sheath ( FIG. 17A ).
- the neurostimulator 18 is progressively advanced in a distal direction until a portion of the neurostimulator body 20 is in flush contact with the lower surface 206 of the hub portion 130 ( FIG. 17B ). As shown in FIG. 17C , the neurostimulator 18 is then advanced towards the handle 126 of the delivery tool 124 until the neurostimulator body 20 snugly engages the tangs 212 and the integral fixation apparatus 26 engages the surface 218 of the hub portion 130 , thereby providing a retention force to keep the neurostimulator securely mated with the delivery tool during implantation.
- a gingival-buccal insertion site in a similar or identical manner as disclosed in the '258 application.
- a #10 scalpel blade (not shown) can be used to make an incision in a horizontal manner between the second and third molars (not shown).
- a first surgical tool (not shown) similar or identical to the one disclosed in the '480 application is inserted into the incision and subperiosteally.
- the anatomy of the subject's skull, including the location and size of the PPF 14 can be determined prior to insertion of the first surgical tool.
- the first surgical tool After inserting the first surgical tool into the incision, the first surgical tool is urged in a posterior direction so that a first major surface of the surgical tool's distal portion traverses under the zygomatic bone 28 along the maxillary tuberosity 120 .
- the first surgical tool is then advanced further until a distal dissecting tip thereof engages the junction formed by the posterior maxillary buttress (not shown) and the pterygoid plate 122 , just inferior and lateral to the PPF 14 . Advancement of the first surgical tool may naturally stop when the distal dissecting tip is correctly positioned at the junction formed by the posterior maxillary buttress and the pterygoid plate 122 .
- the first surgical tool is then withdrawn, thereby creating a surgical access cavity (not shown).
- the delivery tool 124 (with the neurostimulator 18 loaded thereon) can be advanced through the delivery path until the stimulation lead 22 of the neurostimulator is adjacent the PPF 14 (Step 262 ).
- the handle 126 of the delivery tool 124 can be manipulated by, for example, sliding the second component 140 axially away from the first component 138 .
- the second component 140 can be sufficiently advanced (relative to the first component 138 ) to cause the lead ejector 172 of the delivery tool 124 to advance through the central lumen 182 , which causes the stimulation lead 22 to emerge from the seam 252 of the double barrel sheath 136 so that the stimulation lead is in close proximity to the SPG 10 .
- the delivery tool 124 can be withdrawn so that the neurostimulator 18 remains implanted in the subject as disclosed in the '641 patent.
- an electrical current from the neurostimulator can be applied to the SPG 10 to treat a medical condition (e.g., headache).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/265,086, filed Dec. 9, 2015, the entirety of which is hereby incorporated by reference for all purposes.
- The present disclosure relates generally to surgical tools configured to deliver medical devices to a craniofacial region of a subject and, more particularly, to surgical tools configured to deliver an implantable neurostimulator to a pterygopalatine fossa of a subject.
- Electrical stimulation of peripheral and central neural structures has shown increased interest due to the potential benefits it may provide to individuals suffering from many neurological and behavioral diseases. Many of these therapies today are not well accepted due to the invasive nature of the therapy, even though the efficacy is quite good. This has created a need for less invasive therapies that are directed toward patient and physician clinical needs.
- Headaches are one of the most debilitating ailments that afflict millions of individuals worldwide. The specific pathophysiology of headaches is unknown. Known sources of headache pain consist of trauma, vascular, autoimmune, degenerative, infectious, drug and medication-induced, inflammatory, neoplastic, metabolic-endocrine, iatrogenic, musculoskeletal and myofacial causes. Also, even though the possible underlying cause of the headache pain is identified and treated, the headache pain may persist.
- Currently, the sphenopalatine (pterygopalatine) ganglion (SPG) is a target of manipulation in clinical medicine to treat headaches. The SPG is an extracranial neuronal center located behind the nose. It consists of parasympathetic neurons that innervate (in part) the middle cerebral and anterior cerebral blood vessels, the facial blood vessels, and the lacrimal glands. The SPG also consists of sympathetic and sensory nerve fibers that pass through the SPG in route to their end organs. Manipulation of the SPG is mostly performed in attempted treatments of severe headaches, such as cluster headaches or migraines.
- Various clinical approaches have been used for over 100 years to modulate the function of the SPG to treat headaches. These procedures vary from least invasive (e.g., transnasal anesthetic blocks) to much more invasive (e.g., surgical ganglionectomy), as well as procedures, such as surgical anesthetic injections, ablations, gamma knife and cryogenic surgery. These later procedures are very invasive, and most are non-reversible. In both cases, the surgical approach is typically through the nostrils or using a trans-coronoid notch approach.
- One aspect of the present disclosure includes a delivery tool configured to deliver a neurostimulator into a pterygopalatine fossa (PPF) of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion, and a double barrel sheath. The hub portion can be located between the shaft and a spine member that extends axially away from the hub portion. The hub portion can be sized and dimensioned to releasably mate with the neurostimulator. The double barrel sheath can be connected to the spine member. A central lumen can extend through at least a portion of the shaft and the hub portion. The central lumen can be adapted to receive a lead ejector for selective deployment of the stimulation lead from the double barrel sheath.
- Another aspect of the present disclosure includes a method for deploying a neurostimulator in close proximity to a sphenopalatine ganglion (SPG) of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. One step of the method can include loading the neurostimulator onto a delivery tool. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion located between the shaft and a spine member that extends axially away from the hub portion, and a double barrel sheath connected to the spine member. At least a portion of the shaft and the hub portion can include a central lumen extending therethrough. Next, the delivery tool can be advanced so that the stimulation lead of the neurostimulator is adjacent a PPF of the subject. An ejector lead can then be deployed through the central lumen of the delivery tool to cause the stimulation lead to emerge from the double barrel sheath so that the stimulation lead is in close proximity to the SPG. The delivery tool can be withdrawn so that the neurostimulator remains implanted in the subject.
- Another aspect of the present disclosure includes a navigation-compatible delivery tool configured to deliver a neurostimulator into a PPF of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion located between the shaft and a trunk member that extends axially away from the hub portion, a spine member connected to and extending from the trunk member, and a double barrel sheath connected to the spine member.
- Another aspect of the present disclosure includes a navigation-assisted method for deploying a neurostimulator in close proximity to a SPG of a subject. The neurostimulator can include a body connected to an integral stimulation lead having one or more stimulating electrodes. One step of the method can include loading the neurostimulator onto a delivery tool. The delivery tool can comprise a handle, an elongated shaft extending from the handle, a hub portion located between the shaft and a trunk member that extends axially away from the hub portion, a spine member connected to and extending from the trunk member, and a double barrel sheath connected to the spine member. Next, the tool can be advanced so that the stimulation lead of the neurostimulator is adjacent a PPF of the subject. The handle can be manipulated to cause a lead ejector of the delivery tool to displace the stimulation lead from the double barrel sheath so that the stimulation lead is in close proximity to the SPG. The delivery tool can then be withdrawn so that the neurostimulator remains implanted in the subject. The advancing, manipulating, and withdrawing steps can be performed using a navigation system.
- The foregoing and other features of the present disclosure will become apparent to those skilled in the art to which the present disclosure relates upon reading the following description with reference to the accompanying drawings, in which:
-
FIG. 1 is a perspective view showing part of the nervous innervations of the anterior craniofacial skeleton; -
FIG. 2 is a perspective view of an implantable neurostimulator; -
FIG. 3 is a schematic illustration of a delivery tool that is configured to deliver an implantable neurostimulator to a pterygopalatine fossa (PPF) of a subject and constructed in accordance with one aspect of the present disclosure; -
FIG. 4 is a perspective view of a handle comprising the delivery tool inFIG. 3 ; -
FIGS. 5A-B are perspective views of an elongated shaft and hub portion comprising the delivery tool inFIG. 3 ; -
FIG. 5C is a cross-sectional view taken along Line 5C-5C inFIG. 5A ; -
FIG. 6 is a perspective view of a spine member comprising the delivery tool inFIG. 3 ; -
FIG. 7A is a perspective view of a double barrel sheath comprising the delivery tool inFIG. 3 ; -
FIG. 7B is a cross-sectional view taken alongLine 7B-7B inFIG. 7A ; -
FIG. 8 is a process flow diagram illustrating a method for deploying a neurostimulator in close proximity to a sphenopalatine ganglion (SPG) of a subject according to another aspect of the present disclosure; -
FIGS. 9A-C are a series of schematic illustrations showing loading of a neurostimulator onto the delivery tool inFIG. 3 ; -
FIG. 10 is a schematic illustration of a delivery tool that is configured to deliver an implantable neurostimulator to a PPF of a subject and constructed in accordance with one aspect of the present disclosure; -
FIGS. 11A-B are perspective views of a handle comprising the delivery tool inFIG. 10 in an assembled configuration (FIG. 11A ) and an exploded configuration (FIG. 11B ); -
FIGS. 12A-G are a series of schematic illustrations showing an integral lead ejector mechanism of the delivery tool inFIG. 10 ; -
FIGS. 13A-B are perspective views of a hub portion comprising the delivery tool inFIG. 10 ; -
FIG. 13C is a cross-sectional view taken alongLine 13C-13C inFIG. 13A ; -
FIG. 14 is a perspective view of a spine member comprising the delivery tool inFIG. 10 ; -
FIG. 15A is a perspective view of a double barrel sheath comprising the delivery tool inFIG. 10 ; -
FIG. 15B is a cross-sectional view taken alongLine 15B-15B inFIG. 15A ; -
FIG. 15C is a perspective view of the spine member inFIG. 14 mated with the double barrel sheath (FIGS. 15A-C ); -
FIG. 16 is a process flow diagram illustrating a method for deploying a neurostimulator in close proximity to a SPG of a subject according to another aspect of the present disclosure; and -
FIGS. 17A-D are a series of schematic illustrations showing loading and deployment of a neurostimulator from the delivery tool inFIG. 10 . - The present disclosure relates generally to surgical tools configured to deliver medical devices to a craniofacial region of a subject, and more particularly to surgical tools configured to deliver an implantable neurostimulator to a pterygopalatine fossa (PPF) of a subject. As described in more detail below, the delivery tools of the present disclosure are configured to deliver a neurostimulator into a craniofacial region of a subject, such as the PPF. The present disclosure may be employed to assist in treating a variety of chronic or acute medical conditions. Examples of such medical conditions can include, but are not limited to, pain (e.g., headache, facial pain, trigeminal neuralgias, sphenopalatine neuralgias and/or atypical face pain), movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, neurological disorders, urinary bladder disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders.
- Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention pertains.
- In the context of the present disclosure, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” as used herein, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof.
- As used herein, the term “and/or” can include any and all combinations of one or more of the associated listed items.
- As used herein, phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y.
- As used herein, phrases such as “between about X and Y” can mean “between about X and about Y.”
- As used herein, phrases such as “from about X to Y” can mean “from about X to about Y.”
- It will be understood that when an element is referred to as being “on,” “attached” to, “connected” to, “coupled” with, “contacting,” etc., another element, it can be directly on, attached to, connected to, coupled with or contacting the other element or intervening elements may also be present. In contrast, when an element is referred to as being, for example, “directly on,” “directly attached” to, “directly connected” to, “directly coupled” with or “directly contacting” another element, there are no intervening elements present. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
- Spatially relative terms, such as “under,” “below,” “lower,” “over,” “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms can encompass different orientations of the apparatus in use or operation in addition to the orientation depicted in the figures. For example, if the apparatus in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features.
- It will be understood that, although the terms “first,” “second,” etc. may be used herein to describe various elements, these elements should not be limited by these terms. These terms are only used to distinguish one element from another. Thus, a “first” element discussed below could also be termed a “second” element without departing from the teachings of the present disclosure. The sequence of operations (or steps) is not limited to the order presented in the claims or figures unless specifically indicated otherwise.
- As used herein, the term “headache” can refer to migraines, tension headaches, cluster headaches, trigeminal neuralgia, sphenopalatine neuralgia, secondary headaches, tension-type headaches, chronic and episodic headaches, medication overuse/rebound headaches, chronic paroxysmal hemicrinia headaches, hemicranias continua headaches, post-traumatic headaches, post-herpetic headaches, vascular headaches, reflex sympathetic dystrophy-related headaches, cervicalgia headaches, caroidynia headaches, sciatica headaches, trigeminal headaches, occipital headaches, maxillary headaches, chary headaches, paratrigeminal headaches, petrosal headaches, Sluder's headache, vidian headaches, low cerebrospinal fluid pressure headaches, temporomandibular joint (TMJ) headaches, causalgia headaches, myofascial headaches, all primary headaches (e.g., primary stabbing headache, primary cough headache, primary exertional headache, primary headache associated with sexual activity, hypnic headache, and new daily persistent headache), all trigeminal autonomic cephalagias (e.g., paroxysmal hemicranias, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)), chronic daily headaches, occipital neuralgia, atypical facial pain, neuropathic trigeminal pain, and miscellaneous-type headaches.
- As used herein, the term “cluster headache” can refer to extremely painful and debilitating headaches that occur in groups or clusters. Cluster headaches can include chronic or episodic cluster headaches, cluster-type headaches, histamine headaches, histamine cephalalgia, Raedar's syndrome and sphenopalatine neuralgia.
- As used herein, the term “migraine” can refer to an intense and disabling chronic or episodic headache typically characterized by severe pain in one or both sides of the head. Migraines can include, but are not limited to, migraine without aura, migraine with aura, migraine with aura but without headache, menstrual migraines, variant migraines, transformed migraines, menstrual migraine, complicated migraines, hemiplegic migraines, atypical migraines, chronic migraines, basilar-type migraines, childhood periodic syndromes that are commonly precursors of migraine (e.g., abdominal, cyclic vomiting, BPV, etc.), status migrainous, and all types of probable migraines.
- As used herein, the term “facial pain” can refer to direct pain that typically involves nerves supplying the face or, alternatively, indirect (referred) pain from other structures in the head, e.g., blood vessels. The pain may be related to headache (e.g., migraine), muscular syndromes (e.g., TMJ), and herpetic or rheumatic disease or injury.
- As used herein, the terms “modulate” or “modulating” can refer to causing a change in neuronal activity, chemistry and/or metabolism. The change can refer to an increase, decrease, or even a change in a pattern of neuronal activity. The terms may refer to either excitatory or inhibitory stimulation, or a combination thereof, and may be at least electrical, biological, magnetic, optical or chemical, or a combination of two or more of these. The terms can also be used to refer to a masking, altering, overriding, or restoring of neuronal activity.
- As used herein, the term “close proximity” with reference to a portion of an electrode or electrical lead relative to a target nerve structure (e.g., sphenopalatine ganglia or SPG) can refer to a distance between the electrode (or electrical lead) and the target nerve structure sufficient to enable electrical modulation of the target nerve structure. Thus, in some instances, “close proximity” can refer to a distance between the electrode (or electrical lead) and the target nerve structure whereby the electrode (or electrical lead) is not in direct contact with the nerve structure, but electrical modulation of the target nerve structure is still possible. In one example, “close proximity” can mean that the distance between an electrode or electrical lead and a target nerve structure is less than 1 mm but direct contact between structures does not occur. In another example, “close proximity” can mean that the distance between an electrode or electrical lead and a target nerve structure is greater than 1 mm (e.g., about 1 mm to about 1 cm), but direct contact between structures does not occur.
- As used herein, the term “subject” can refer to any warm-blooded organism including, but not limited to, human beings, pigs, rats, mice, dogs, goats, sheep, horses, monkeys, apes, rabbits, cattle, etc.
- As used herein, the term “prevent” shall have its plain and ordinary meaning to one skilled in the art of pharmaceutical or medical sciences. For example, “prevent” can mean to stop or hinder a medical condition, such as a headache.
- As used herein, the terms “treat” or “treating” shall have their plain and ordinary meaning to one skilled in the art of pharmaceutical or medical sciences. For example, “treat” or “treating” can mean to prevent or reduce a medical condition, such as a headache.
- As used herein, the term “medical condition” can refer to pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, urinary bladder disorders, abnormal metabolic states, disorders of the muscular system, infectious and parasitic diseases, neoplasms, endocrine diseases, nutritional and metabolic diseases, immunological diseases, diseases of the blood and blood-forming organs, mental disorders, diseases of the nervous system, diseases of the sense organs, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the genitourinary system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, congenital anomalies, certain conditions originating in the perinatal period, and symptoms, signs, and ill-defined conditions.
- Pain treatable by the present invention can be caused by conditions including, but not limited to, migraine headaches, including migraine headaches with aura, migraine headaches without aura, menstrual migraines, migraine variants, atypical migraines, complicated migraines, hemiplegic migraines, transformed migraines, and chronic daily migraines, episodic tension headaches, chronic tension headaches, analgesic rebound headaches, episodic cluster headaches, chronic cluster headaches, cluster variants, chronic paroxysmal hemicranias, hemicrania continua, post-traumatic headache, post-traumatic neck pain, post-herpetic neuralgia involving the head or face, pain from spine fracture secondary to osteoporosis, arthritis pain in the spine, headache related to cerebrovascular disease and stroke, headache due to a vascular disorder, reflex sympathetic dystrophy, cervicalgia (which may be due to various causes including, but not limited to, muscular, discogenic or degenerative, including arthritic, posturally related or metastatic), glossodynia, carotidynia, cricoidynia, otalgia due to middle ear lesion, gastric pain, sciatica, maxillary neuralgia, laryngeal pain, myalgia of neck muscles, trigeminal neuralgia (sometimes also termed tic douloureux), post-lumbar puncture headache, low cerebro-spinal fluid pressure headache, TMJ joint disorder, atypical facial pain, ciliary neuralgia, paratrigeminal neuralgia (sometimes also termed Raeder's syndrome), petrosal neuralgia, Eagle's syndrome, idiopathic intracranial hypertension, orofacial pain, myofascial pain syndrome involving the head, neck and shoulder, chronic migraneous neuralgia, cervical headache, paratrigeminal paralysis, sphenopalatine ganglion neuralgia (sometimes also termed lower-half headache, lower facial neuralgia syndrome, Sluder's neuralgia and Sluder's syndrome), carotidynia, vidian neuralgia, causalgia, atypical odontalgia, cluster tic syndrome, geniculate neuralgia, glossopharyngeal neuralgia, occipital neuralgia and temporal arteritis and/or a combination of the above.
- Movement disorders treatable by the present invention may be caused by conditions including, but not limited to, Parkinson's disease, cerebropalsy, dystonia, essential tremor and hemifacial spasms.
- Epilepsy treatable by the present invention may be, for example, generalized or partial.
- Cerebrovascular disease treatable by the present invention may be caused by conditions including, but not limited to, aneurysms, strokes, and cerebral hemorrhage.
- Autoimmune diseases treatable by the present invention include, but are not limited to, multiple sclerosis.
- Sleep disorders treatable by the present invention may be caused by conditions including, but not limited to, circadian rhythm disorders, sleep apnea and parasomnias.
- Autonomic disorders treatable by the present invention may be caused by conditions including, but not limited to, gastrointestinal disorders, including but not limited to gastrointestinal motility disorders, nausea, vomiting, diarrhea, chronic hiccups, gastroesphageal reflux disease, and hypersecretion of gastric acid, autonomic insufficiency, autonomic instability, excessive epiphoresis, excessive rhinorrhea, and cardiovascular disorders including, but not limited, to cardiac dysrythmias and arrythmias, hypertension, carotid sinus disease, Holmes-adie syndrome, orthostatic hypotension, striatonigral degeneration, vasovagal syncope, lyme disease and autonomic instability.
- Neurological disorders treatable by the inventive method may be caused by conditions including, but not limited to: hemifacial spasm, Melkersson-Rosenthal Syndrome and Parry-Romberg syndrome.
- Urinary bladder disorders treatable by the present invention may be caused by conditions including, but not limited to, spastic or flaccid bladder.
- Abnormal metabolic states treatable by the present invention may be caused by conditions including, but not limited to, hyperthyroidism or hypothyroidism.
- Disorders of the muscular system treatable by the present invention can include, but are not limited to, muscular dystrophy, and spasms of the upper respiratory tract and face.
- Neuropsychiatric or mental disorders treatable by the present invention may be caused by conditions including, but not limited to, depression, schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
- A brief discussion of the pertinent anatomy and neurophysiology is provided to assist the reader with understanding the present invention. The autonomic nervous system innervates numerous pathways within the human body and consists of two divisions: the sympathetic and the parasympathetic nervous systems. The sympathetic and parasympathetic nervous systems are antagonistic in their action, balancing the other system's effects within the body. The sympathetic nervous system (SNS) usually initiates activity within the body, preparing the body for action, while the parasympathetic nervous system (PNS) primarily counteracts the effects of the SNS.
- The SPG 10 (
FIG. 1 ) are located on both sides of the head. It shall be assumed for the following discussion of the present invention that reference is being made to theSPG 10 located on the left side of the head. TheSPG 14 10 located behind theposterior maxilla 12 thePPF 14, posterior to the middle nasal turbinate (not shown in detail). TheSPG 10 is part of the parasympathetic division of the autonomic nervous system; however, the SPG has both sympathetic and parasympathetic nerve fibers, as well as sensory and motor nerve fibers either synapsing within the ganglion (e.g., parasympathetic) or fibers that are passing through the ganglion and not synapsing (e.g., sympathetic, sensory and motor). - The parasympathetic activity of the
SPG 10 is mediated through the greater petrosal nerve (not shown), while the sympathetic activity of the SPG is mediated through the deep petrosal nerve (not shown), which is essentially an extension of the cervical sympathetic chain (not shown). Sensory sensations generated by or transmitted through theSPG 10 include, but are not limited to, sensations to the upper teeth, feelings of foreign bodies in the throat, and persistent itching of the ear. TheSPG 10 transmits sensory information, including pain, to the trigeminal system via the maxillary division (not shown). - One aspect of the present disclosure includes a delivery tool 16 (
FIG. 3 ) configured to deliver a neurostimulator into a craniofacial region of a subject. In some instances, the neurostimulator can be configured for implantation in thePPF 14. In other instances, the neurostimulator is sized and configured for implantation on aposterior maxilla 12. A neurostimulator capable of being delivered by thedelivery tool 16 can generally include any active implantable medical device configured to deliver electrical stimulation, alone or in combination with other types of stimulation to tissue of a subject. The neurostimulator can further include any active implantable medical device configured for implantation for a relatively short period of time (e.g., to address acute medical conditions) or a relatively long period of time (e.g., to address chronic medical conditions). Additionally, the neurostimulator can include one or more elements used to record or monitor a physiological response of a subject's tissue (e.g., a delivered therapy), as well as one or more other components that interface with the patient's tissue (e.g., therapeutic agent delivery mechanisms, sensors, etc.). - In one example of the present disclosure, a
neurostimulator 18 can be configured as shown inFIG. 2 and disclosed in U.S. Pat. No. 8,494,641 to Boling et al. (hereinafter, “the '641 patent”), the entirety of which is hereby incorporated by reference. Briefly, theneurostimulator 18 can comprise astimulator body 20, anintegral stimulation lead 22, which includes one or more stimulating electrodes 24, and anintegral fixation apparatus 26. Theneurostimulator 18 can be implanted as disclosed in the '641 patent, i.e., such that thestimulator body 20 is positioned sub-periosteally medial to the zygoma 28 (FIG. 1 ) on theposterior maxilla 12 within the buccal fat pad (not shown) of the cheek, and the integral fixation apparatus 26 (FIG. 2 ) is anchored to the zygomaticomaxillary buttress 30 (FIG. 1 ) such that the integral stimulation lead 22 (FIG. 2 ) is placed within the PPF 14 (FIG. 1 ) or, more specifically, in close proximity (e.g., about 1-5 mm) to theSPG 10. - The delivery tool 16 (
FIG. 3 ) of the present disclosure is designed and configured to facilitate delivery of a neurostimulator in close proximity to the SPG 10 (FIG. 1 ) so that targeted electrical stimulation or delivery of electrical current from the neurostimulator to the SPG can be accomplished. Although reference below is made to theneurostimulator 18 inFIG. 2 , it shall be appreciated that any variety of neurostimulator may be used as part of the present disclosure. Referring toFIG. 3 , thedelivery tool 16 can comprise ahandle 32, anelongated shaft 34 extending from the handle, ahub portion 36 located between the shaft and aspine member 38, and adouble barrel sheath 40 connected to the spine member. As described in more detail below, thedelivery tool 16 is designed and configured to be inserted trans-orally from an incision located on the posterior maxilla 12 (FIG. 1 ). - In some instances, the delivery tool 16 (
FIG. 3 ) can have a length L of about 10 cm to about 30 cm. In one example, thedelivery tool 16 can have a length L of about 14 cm. All or only a portion of thedelivery tool 16 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as titanium or stainless steel, medical grade plastics (e.g., PEEK, polycarbonate, nylon), glass, ceramics (e.g., aluminum, zirconium oxide), combinations of metals, ceramics, plastics or plastic composites, and the like. - In another aspect, the
handle 32 can be ergonomically formed and have a length of about 6 cm to about 12 cm. Thehandle 32 can vary in diameter from a proximal end 42 (e.g., about 0.5 cm to about 3 cm) to a distal end 44 (e.g., about 0.5 cm to about 2 cm) thereof. Thehandle 32 can include various features to provide grip and tactile maneuverability, such as circumferential ridges or a cross-hatched precut pattern (not shown) into the material forming the handle. As shown inFIG. 4 , thehandle 32 can include a series of radially spaced apart depressions 46 (e.g., three) to provide a user with not only grip and tactile maneuverability, but also a visual cue to assist with proper positioning and orientation of theneurostimulator 18 during delivery. Thehandle 32 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, and the like. - In another aspect, the elongated shaft 34 (
FIGS. 5A-C ) of thedelivery tool 16 includes oppositely disposed first andsecond end portions first end portion 48 is sized and dimensioned for insertion into achannel 52 of thehandle 32. Thesecond end portion 50 is securely connected to, or integrally formed with, thehub portion 36 of thedelivery tool 16. Theelongated shaft 34 can have any desired length and diameter. In some instances, the length of theelongated shaft 34 can be about 3 cm to about 7 cm. In one example, the length of theelongated shaft 34 can be about 4.5 cm. The diameter of theelongated shaft 34 can be about 0.1 cm to about 1 cm. In one example, the diameter of theelongated shaft 34 can be about 0.3 cm. In some instances, the diameter of theelongated shaft 34 can be uniform between the first andsecond end portions elongated shaft 34 can taper from thefirst end portion 48 to the second end portion 50 (or vice-versa). Theelongated shaft 34 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like. - The
elongated shaft 34 also includes an opening orslot 54. Theslot 54 can be located about any portion of theelongated shaft 34. In one example, theslot 54 is located at or about the middle of theelongated shaft 34. Although theslot 54 is shown inFIGS. 5A-C as having a rectangular shape, it will be appreciated that the slot can have any desired shape (e.g., circular, square, ovoid, etc.). Theslot 54 forms part of a central lumen 56 (FIG. 5C ), which extends through theelongated shaft 34 from the slot, through thesecond end portion 50, and through thehub portion 36. As described in more detail below, the slot 54 (and the central lumen 56) is adapted to receive an ejector lead 58 (FIGS. 9A-C ) therethrough. - The hub portion 36 (
FIGS. 5A-C ) is located between theelongated shaft 34 and thespine member 38. Thehub portion 36 is sized and configured to releasably mate with aneurostimulator 18. Thehub portion 36 comprises aport 60 configured to slidably receive astimulator body 20 of theneurostimulator 18. Theport 60 is defined by alower surface 62, which is integrally formed with oppositely disposedside walls 64, as well as anupper portion 66 that includes a plurality oftangs 68. Although not shown, it will be appreciated that theupper portion 66 can include only onetang 68. - As mentioned above, a portion of the central lumen 56 extends through the
hub portion 36. Thehub portion 36 thus includes asecond opening 70 that is in fluid communication with the central lumen 56. Thesecond opening 70 can be shaped like a bowling pin such that afirst portion 72 thereof is adapted to receive thespine member 38, and asecond portion 74 thereof is adapted to receive thedouble barrel sheath 40. Thehub portion 36 can further include one ormore channels 76 that extend from thelower surface 62 into the central lumen 56. The channel(s) 76 are sized and dimensioned to receive a fastener (not shown), such as a dowel to connect thespine member 38 to thehub portion 36. In one example, thehub portion 36 can include twochannels 76 of identical diameter and length, each of which is adapted to receive a dowel. - The
lower surface 62 can be sized and dimensioned to allow thehub portion 36 to releasably mate with theneurostimulator 18. In one example, thelower surface 62 can have a length of about 0.5 cm to about 2 cm (e.g., about 1 cm). In another example, thelower surface 62 can have a width of about 0.5 cm to about 2 cm (e.g., about 1 cm). Each of the oppositely disposedside walls 64 can have any desired height, such as about 0.1 cm to about 0.5 cm (e.g., about 0.3 cm). As shown inFIG. 5A , each of theside walls 64 can have a contouredarcuate portion 78. - The
tangs 68, in addition to thelower surface 62 and theside walls 64 are configured to provide a retention force when thestimulator body 20 is received in theport 60. Each of thetangs 68 includes anoverhang portion 80 for contacting a portion of the stimulator body 20 (e.g., when theneurostimulator 18 is disposed in the port 60). Each of theoverhang portions 80 permits the amount of a retention force between thestimulator body 20 and thehub portion 36 to be selectively adjusted. For example, bending of theintegral fixation apparatus 26 of theneurostimulator 18 towards asurface 82 of theupper portion 66 creates opposing forces between theoverhang portions 80 and a surface of thestimulator body 20. Increasing an adjustment angle of theintegral fixation apparatus 26 towards thesurface 82 results in an increased retention force. Removal of the retention force during retraction requires theintegral fixation apparatus 26 to be pushed away from thesurface 82. - The
hub portion 36 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like. Thehub portion 36 is configured to hold or carry theneurostimulator body 20 during placement of theneurostimulator 18. Thus, one skilled in the art will appreciate that the amount of material used to form thehub portion 36 should be minimized to reduce the amount of tissue dissection needed to place theneurostimulator 18 in vivo, as well as to reduce the amount of drag that occurs during placement and removal of thedelivery tool 16. - In another aspect, the spine member 38 (
FIG. 6 ) extends axially away from, and is securely connected to, thehub portion 36. Thespine member 38 has an elongated configuration and includes aproximal end portion 84, adistal end portion 86, and anintermediate portion 88 extending between the proximal and distal end portions. Theproximal end portion 84 is adapted for connection to thehub portion 36 via one or more channel(s) 90, which is/are configured to receive a fastener, such as a dowel. In one example, theproximal end portion 84 can include twochannels 90 of an identical diameter and length, each of which is adapted to receive a dowel. - The
spine member 38 can have any desired length and width. In one example, thespine member 38 can have a length of about 4 cm to about 6 cm (e.g., about 5 cm). In another example, thespine member 38 can have a width of about 0.1 cm to about 0.8 cm (e.g., about 0.3 cm). Thespine member 38 can have a uniform width or, alternatively, the width of the spine member can taper from a first width at theproximal end portion 84 that is greater than a second width at thedistal end portion 86. In some instances, adistal tip 92 of thespine member 38 can include a tapered arcuate end. In other instances, thedistal tip 92 can be bulbous or mushroom-shaped. In some instances, thespine member 38 can have a square-shaped cross-sectional profile; however, it will be appreciated that other cross-sectional profiles are possible (e.g., semi-circular, circular, rectangular, etc.). - In some instances, the
distal end portion 86 of thespine member 38 can extend at an angle A relative to a longitudinal plane P of theproximal end portion 84. In one example, the angle A can be about 10° to about 45°, depending upon the craniofacial anatomy of the subject. - The
spine member 38 can have a rigid, semi-rigid, or flexible configuration. Thespine member 38 can be made from one or combination of rigid, semi-rigid, or flexible materials, such as metals, metal alloys, and polymers or plastics. In some instances, all or only a portion of thespine member 38 can be malleable. For example, only thedistal end portion 86 of thespine member 38 can be malleable. In another example, thespine member 38 can be made of a malleable metal that supports thedouble barrel sheath 40 and the integral stimulation lead 22 from buckling when longitudinal or lateral forces are encountered. The malleability allows a physician to conform the shape of the neurostimulator 18 (e.g., the integral stimulation lead 22) to correspond to a patient's anatomy and thereby aid with implantation. Malleability in some cases is not required; thus, aspine member 38 made from a non-malleable material, such as plastic can also serve the intended function. - In another aspect, the double barrel sheath 40 (
FIGS. 7A-B ) is connected to thespine member 38. Thedouble barrel sheath 40 comprises afirst barrel 94 and asecond barrel 96. Afirst lumen 98 and asecond lumen 100 extend through the first andsecond barrels FIG. 7B , thedouble barrel sheath 40 can have an hour glass-like or figure eight-like cross-sectional profile. Thefirst lumen 98 is shaped and dimensioned to receive thespine member 38. For example, all or only a portion of thespine member 38 can be disposed within thefirst lumen 98. In some instances, thespine member 38 is connected to an inner surface (not shown) defining thefirst lumen 98 by any one or combination of attachment mechanisms, such as adhesives, pins, staples, etc. Thesecond lumen 100 is shaped and dimensioned to partially receive theintegral stimulation lead 22 of theneurostimulator 18. Afirst end 102 of thedouble barrel sheath 40 is securely connected to thesecond opening 70 of thehub portion 36 such that the central lumen 56 is in fluid communication with thesecond lumen 100. Thedouble barrel sheath 40 can be securely connected to thehub portion 36 by any one or combination of attachment mechanisms, such as adhesives, pins, staples, etc. - In some instances, the
double barrel sheath 40 can be made of a semi-flexible material (or materials). In one example, thedouble barrel sheath 40 can be formed from a plastic or polymer, such as polytetrafluoroethylene. In other instances, thedouble barrel sheath 40 can be formed from a flexible material having a thickness of about 0.04 inches to about 0.001 inches. - In some instances, the
second barrel 96 of thesheath 40 has a splittable configuration to allow for removal or deployment of theintegral stimulation lead 22 of the neurostimulator 18 from the sheath with minimal load on the integral stimulation lead. A partial section of thesecond barrel 96 can include aseam 104 adapted to permit egress of thestimulation lead 22 from thesecond lumen 100 during deployment of theneurostimulator 18. Theseam 104 can extend from asecond end 106 of thesheath 40 to anopening 108, which is located at or about the midpoint of thesecond barrel 96. In some instances, the distance between thesecond end 106 and theopening 108 can be equal to, or about equal to, the length of thestimulation lead 22. Theseam 104 allows for removal or deployment of theintegral stimulation lead 22 of the neurostimulator 18 from thesheath 40 with minimal load on the integral stimulation lead. Undesirable loading on theintegral stimulation lead 22 can cause migration of the lead away from the desired implant location during withdrawal of thedelivery tool 16. Advantageously, only theseam 104 of thesheath 40 is parted during deployment of theneurostimulator 18, which reduces the load on theintegral stimulation lead 22. - Another aspect of the present disclosure is illustrated in
FIG. 8 and includes amethod 110 for deploying aneurostimulator 18 in close proximity to aSPG 10 of a subject. Themethod 110 can generally include the steps of: loading aneurostimulator 18 onto a delivery tool (Step 112); advancing thedelivery tool 16 to a PPF 14 (Step 114); deploying anejector lead 58 of the delivery tool (Step 116); and withdrawing the delivery tool from the subject (Step 118). In one example of themethod 110, thedelivery tool 16 is configured as shown inFIG. 3 and described above, and theneurostimulator 18 is configured as shown inFIG. 2 and described in the '641 patent. - Either prior to, contemporaneous with, or following
Step 112, a delivery path can be surgically formed in the subject as disclosed in U.S. patent application Ser. No. 13/470,480 (hereinafter, “the '480 application”), which is hereby incorporated by reference in its entirety. Loading of theneurostimulator 18 onto thedelivery tool 16 is illustrated inFIGS. 9A-C . To do so, theneurostimulator 18 is first brought into close proximity with thehub portion 36 of thedelivery tool 16. Theneurostimulator 18 is then angled slight downward toward thedouble barrel sheath 40 of thedelivery tool 16 until a distal portion of theintegral stimulator lead 22 is introduced or inserted into theopening 108 of the sheath (FIG. 9A ). Next, theneurostimulator 18 is progressively advanced in a distal direction until a portion of theneurostimulator body 20 is in flush contact with thelower surface 62 of the hub portion 36 (FIG. 9B ). As shown inFIG. 9C , theneurostimulator 18 is then advanced towards thehandle 32 of thedelivery tool 16 until theneurostimulator body 20 snugly engages thetangs 68 and theintegral fixation apparatus 26 engages thesurface 82 of thehub portion 36, thereby providing a retention force to keep the neurostimulator securely mated with the delivery tool during implantation. - To form the delivery path, a gingival-buccal insertion site in a similar or identical manner as disclosed in U.S. Patent Publication No. 2010/0185258 A1 (hereinafter, “the '258 application”), which is hereby incorporated by reference in its entirety. In one example, a #10 scalpel blade (not shown) can be used to make an incision in a horizontal manner between the second and third molars (not shown). Next, a first surgical tool (not shown) similar or identical to the one disclosed in the '480 application is inserted into the incision and subperiosteally. In some instances, the anatomy of the subject's skull, including the location and size of the
PPF 14 can be determined prior to insertion of the first surgical tool. After inserting the first surgical tool into the incision, the first surgical tool is urged in a posterior direction so that a first major surface of the surgical tool's distal portion traverses under thezygomatic bone 28 along themaxillary tuberosity 120. The first surgical tool is then advanced further until a distal dissecting tip thereof engages the junction formed by the posterior maxillary buttress (not shown) and thepterygoid plate 122, just inferior and lateral to thePPF 14. Advancement of the first surgical tool may naturally stop when the distal dissecting tip is correctly positioned at the junction formed by the posterior maxillary buttress and thepterygoid plate 122. The first surgical tool is then withdrawn, thereby creating a surgical access cavity (not shown). - After forming the delivery path, the delivery tool 16 (with the
neurostimulator 18 loaded thereon) can be advanced through the delivery path until thestimulation lead 22 of the neurostimulator is adjacent the PPF 14 (Step 114). As shown inFIG. 9A , anejector lead 58 is then inserted into theslot 54 of thedelivery tool 16. In one example, theejector lead 58 can comprise an electrode lead blank configured to have the same or substantially the same dimensions as theintegral stimulation lead 22 of theneurostimulator 18. At Step 116, theejector lead 58 can be progressively advanced through theslot 54 and the central lumen 56 to cause thestimulation lead 22 to emerge from theseam 104 of thedouble barrel sheath 40 so that the stimulation lead is in close proximity to theSPG 10. - At
Step 118, thedelivery tool 16 can be withdrawn so that theneurostimulator 18 remains implanted in the subject as disclosed in the '641 patent. Following completion of the surgery, and with theneurostimulator 18 securely implanted within the subject, an electrical current from the neurostimulator can be applied to theSPG 10 to treat a medical condition (e.g., headache). - In another aspect of the present disclosure, a navigation-
compatible delivery tool 124 is illustrated inFIG. 10 . Thedelivery tool 124 is configured to deliver, with navigation assistance, a neurostimulator into a craniofacial region of a subject. Non-limiting examples of navigation systems with which thedelivery tool 124 is compatible can include those commercially available from BRAINLAB (Westchester, Ill.), such as the KICK or CURVE systems, the FUSION ENT navigation system (Medtronic, Minneapolis, Minn.), and the NAV3 Navigation Platform (Stryker, Kalamazoo, Mich.). In some instances, the neurostimulator can be configured for implantation in thePPF 14. In other instances, the neurostimulator is sized and configured for implantation on aposterior maxilla 12. A neurostimulator capable of being delivered by thedelivery tool 124 can generally include any active implantable medical device configured to deliver electrical stimulation, alone or in combination with other types of stimulation to tissue of a subject. The neurostimulator can further include any active implantable medical device configured for implantation for a relatively short period of time (e.g., to address acute medical conditions) or a relatively long period of time (e.g., to address chronic medical conditions). Additionally, the neurostimulator can include one or more elements used to record or monitor a physiological response of a subject's tissue (e.g., a delivered therapy), as well as one or more other components that interface with the patient's tissue (e.g., therapeutic agent delivery mechanisms, sensors, etc.). One example of aneurostimulator 18 is shown inFIG. 2 and described above. - The
delivery tool 124 of the present disclosure is designed and configured to facilitate delivery of a neurostimulator in close proximity to theSPG 10 so that targeted electrical stimulation or delivery of electrical current from the neurostimulator to the SPG can be accomplished. Although reference below is made to theneurostimulator 18 inFIG. 2 , it shall be appreciated that any variety of neurostimulator may be used as part of the present disclosure. Referring toFIG. 10 , thedelivery tool 124 can comprise ahandle 126, anelongated shaft 128 extending from the handle, ahub portion 130 located between the shaft and atrunk member 132 that extends axially away from the hub portion, aspine member 134 connected to and extending from the trunk member, and adouble barrel sheath 136 connected to the spine member. As described in more detail below, thedelivery tool 124 is designed and configured to be inserted trans-orally from an incision located on the posterior maxilla 12 (FIG. 1 ). - In some instances, the delivery tool 124 (
FIG. 10 ) can have a length L of about 10 cm to about 30 cm. In one example, thedelivery tool 124 can have a length L of about 14 cm. All or only a portion of thedelivery tool 124 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as titanium or stainless steel, medical grade plastics (e.g., PEEK, polycarbonate, nylon), glass, ceramics (e.g., aluminum, zirconium oxide), combinations of metals, ceramics, plastics or plastic composites, and the like. - In another aspect, the handle 126 (
FIGS. 11A-B ) can be ergonomically shaped and comprise afirst component 138 and asecond component 140. Thehandle 126 can have a length of about 6 cm to about 12 cm. Thehandle 126 can vary in diameter from a proximal end 142 (e.g., about 0.5 cm to about 3 cm) to a distal end 144 (e.g., about 0.5 cm to about 2 cm) thereof. Afirst end portion 146 of thefirst component 138 can include a channel 148 adapted to receive a portion of thesecond component 140. Thefirst component 138 can include various features to provide grip and tactile maneuverability, such as circumferential ridges or a cross-hatched precut pattern (not shown) into the material forming the handle. As shown inFIGS. 11A-B , thehandle 126 can include a series of radially spaced apart depressions 150 (e.g., three) to provide a user with not only grip and tactile maneuverability, but also a visual cue to assist with proper positioning and orientation of theneurostimulator 18 during delivery. The first andsecond components - The
second component 140 of thehandle 126 can have a generally T-shaped configuration that includes afirst end portion 152, asecond end portion 154, and amain body 156 extending between the first and second end portions. Thefirst end portion 152 comprises acap member 158 having a diameter that is greater than a diameter of themain body 156 and thesecond end portion 154. Alumen 160 that is adapted to receive theelongated shaft 128 extends between the first andsecond end portions main body 156 and thesecond end portion 154 of thesecond component 140 can have a tubular or cylindrical shape, and be sized and dimensioned to fit within the channel 148 of thefirst component 138. When thesecond component 140 is received within the channel 148, anannular lip 162 comprising thecap member 158 can directly contact, and be flush with, afirst end surface 164 of thefirst component 138. Thesecond end portion 154 of thesecond component 140 also includes a step 166, which, as described in more detail below, forms part of an integral lead ejector mechanism of thedelivery tool 124. -
FIGS. 12A-G illustrate the integral lead ejector mechanism, which comprises thehandle 126, theelongated shaft 128, aconnector component 168, a plurality offasteners 170, and anejector lead 172. Unlike thedelivery tool 16 described above, which requires tactile manipulation and insertion of theejector lead 58 during operation, theejector lead 172 of thedelivery tool 124 is an integral component thereof and thereby obviates the need to externally feed an ejector lead into the delivery tool during neurostimulator deployment. Advantageously, the integral lead ejector mechanism reduces the time needed to implant aneurostimulator 18 and minimizes the potential for introducing contaminated equipment during a surgical procedure. - Referring to
FIG. 12B , theelongated shaft 128 can extend through thesecond component 140 of thehandle 126. Theconnector component 168 can be seated on the step 166 of thesecond component 140 and secured thereto by a plurality ofscrews 174. When thesecond component 140 and theelongated shaft 128 are mated as shown inFIG. 12B , a plurality ofdowels 176 can extend through thefirst component 138 of thehandle 126 into the elongated shaft to secure the elongated shaft in place. - In another aspect, the elongated shaft 128 (
FIGS. 12C-D ) includes oppositely disposed first andsecond end portions central lumen 182 extending therebetween. Thesecond portion 180 of theelongated shaft 128 is sized and dimensioned for insertion into thelumen 160 of thesecond component 140 of thehandle 126. Thefirst end portion 178 is securely connected to, or integrally formed with, thehub portion 130 of thedelivery tool 124. Theelongated shaft 128 can have any desired length and diameter. In some instances, the length of theelongated shaft 128 can be about 3 cm to about 7 cm. In one example, the length of theelongated shaft 128 can be about 4.5 cm. The diameter of theelongated shaft 128 can be about 0.1 cm to about 1 cm. In one example, the diameter of theelongated shaft 128 can be about 0.3 cm. In some instances, the diameter of theelongated shaft 128 can be uniform between the first andsecond end portions elongated shaft 128 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like. - The
elongated shaft 128 also includes an opening orslot 184. Theslot 184 can be located about any portion of theelongated shaft 128. In one example, theslot 184 is located at or about thesecond end portion 180 of theelongated shaft 128. Although theslot 184 is shown inFIG. 12C as having a rectangular shape, it will be appreciated that the slot can have any desired shape (e.g., circular, square, ovoid, etc.). Theslot 184 forms part of thecentral lumen 182, which extends through theelongated shaft 128 from the slot, through thefirst end portion 178, and through thehub portion 130. As described in more detail below, the slot 184 (and the central lumen 182) is adapted to receive an ejector lead 172 (FIG. 12G ) therethrough. - As shown in
FIGS. 12E-F , theconnector component 168 has a half-moon or semi-circular shape, and includes a plurality ofchannels 186 extending between first and secondmajor surfaces channels 186 is adapted to receive a fastener (e.g., a screw 174) so that theconnector component 168 can be secured to thesecond component 140 of thehandle 126. As shown inFIG. 12F , the secondmajor surface 190 includes agroove 192, which is located between thechannels 186 and extends between oppositely disposed first andsecond edges connector component 168. Thegroove 192 is adapted to receive an L-shaped portion of theejector lead 172. Theconnector component 168 can be formed from one or a combination of materials, such as a medical grade metal or metal alloy, medical grade plastics, polymers, or the like. - The
ejector lead 172 is illustrated inFIG. 12G . Theejector lead 172 has a generally L-shaped configuration and includes afirst end portion 198, a second end portion 200, and amain body portion 202 extending between the first and second end portions. Each of thefirst end portion 198 and themain body portion 202 have an elongated, wire-like shape adapted for insertion into thecentral lumen 182 of theelongated shaft 128. The second end portion 200 has an L- or elbow-shaped configuration and is adapted to extend through theslot 184 of theelongated shaft 128. As discussed in more detail below, theejector lead 172 functions to displace thestimulation lead 22 of the neurostimulator 18 from thedouble barrel sheath 136 during operation of thedelivery tool 124. - The
hub portion 130 is located between theelongated shaft 128 and atrunk member 132. Thehub portion 130 is sized and configured to releasably mate with aneurostimulator 18. Thehub portion 130 comprises aport 204 configured to slidably receive astimulator body 20 of theneurostimulator 18. Theport 204 is defined by alower surface 206, which is integrally formed with oppositely disposedside walls 208, as well as anupper portion 210 that includes a plurality oftangs 212. Although not shown, it will be appreciated that theupper portion 210 can include only onetang 212. - As mentioned above, a portion of the
central lumen 182 extends through thehub portion 130. Thehub portion 130 thus includes a second opening (not shown) that is in fluid communication with thecentral lumen 182. Thelower surface 206 can be sized and dimensioned to allow thehub portion 130 to releasably mate with theneurostimulator 18. In one example, thelower surface 206 can have a length of about 0.5 cm to about 2 cm (e.g., about 1 cm). In another example, thelower surface 206 can have a width of about 0.5 cm to about 2 cm (e.g., about 1 cm). Each of the oppositely disposedside walls 208 can have any desired height, such as about 0.1 cm to about 0.5 cm (e.g., about 0.3 cm). As shown inFIG. 14A , each of theside walls 208 can have a contouredarcuate portion 214. - The
tangs 212, in addition to thelower surface 206 and theside walls 208, are configured to provide a retention force when thestimulator body 20 is received in theport 204. Each of thetangs 212 includes anoverhang portion 216 for contacting a portion of the stimulator body 20 (e.g., when theneurostimulator 18 is disposed in the port 204). Each of theoverhang portions 216 permits the amount of a retention force between thestimulator body 20 and thehub portion 130 to be selectively adjusted. For example, bending of theintegral fixation apparatus 26 of theneurostimulator 18 towards asurface 218 of theupper portion 210 creates opposing forces between theoverhang portions 216 and a surface of thestimulator body 20. Increasing an adjustment angle of theintegral fixation apparatus 26 towards thesurface 218 results in an increased retention force. Removal of the retention force during retraction requires theintegral fixation apparatus 26 to be pushed away from thesurface 218. - The
hub portion 130 can be made of a rigid or semi-rigid medical grade metal or metal alloy, such as stainless steel, medical grade plastics, polymers, or the like. Thehub portion 130 is configured to hold or carry theneurostimulator body 20 during placement of theneurostimulator 18. Thus, one skilled in the art will appreciate that the amount of material used to form thehub portion 130 should be minimized to reduce the amount of tissue dissection needed to place theneurostimulator 18 in vivo, as well as to reduce the amount of drag that occurs during placement and removal of thedelivery tool 124. - In another aspect, the trunk member 132 (
FIGS. 13A-C ) is connected to (e.g., integrally formed with) and extends axially away from thehub portion 130. Thetrunk member 132 has an arcuate, elongated configuration and includes aproximal end portion 220, adistal end portion 222, and anintermediate portion 224 extending between the proximal and distal end portions. Theproximal end portion 220 is connected (e.g., directly connected) to thehub portion 130. Thetrunk member 132 can have any desired length and width. In one example, thetrunk member 132 can have a length of about 4 cm to about 6 cm (e.g., about 5 cm). In another example, thetrunk member 132 can have a width of about 0.1 cm to about 0.8 cm (e.g., about 0.3 cm). - In some instances, the
distal end portion 222 of thetrunk member 132 can extend at an angle A (FIG. 14C ) relative to a longitudinal plane P of theproximal end portion 220. In one example, the angle A can be about 10° to about 45°, depending upon the craniofacial anatomy of the subject. - First and second channels 226 and 228 can extend between the proximal and
distal end portions trunk member 132. The first channel 226 can be in fluid communication with thecentral lumen 182 of thehub portion 130 and theelongated shaft 128. In one example, the first channel 226 can have a circular cross-sectional shape. The second channel 228 can be sized and dimensioned to receive thespine member 134. In one example, the second channel 228 can have a rectangular cross-sectional profile. Thetrunk member 132 can include achannel 230 extending from anupper surface 232 thereof into communication with the second channel 228. Thechannel 230 is adapted to receive a fastener (e.g., a dowel) for securing thespine member 134 within the second channel 228. - In another aspect, the spine member 134 (
FIG. 14 ) extends axially away from, and is securely connected to, thetrunk member 132. Thespine member 134 has an elongated configuration and includes aproximal end portion 234, adistal end portion 236, and anintermediate portion 238 extending between the proximal and distal end portions. Theproximal end portion 234 is adapted for connection to thetrunk member 132 via insertion into the second channel 228. Thespine member 134 can be secured in the second channel 228 by a fastener (e.g., a dowel) inserted through thechannel 230 of thetrunk member 132. - The
spine member 134 can have any desired length and width. In one example, thespine member 134 can have a length of about 4 cm to about 6 cm (e.g., about 5 cm). In another example, thespine member 134 can have a width of about 0.1 cm to about 0.8 cm (e.g., about 0.3 cm). Thespine member 134 can have a uniform width or, alternatively, the width of the spine member can taper from a first width at theproximal end portion 234 that is greater than a second width at thedistal end portion 236. In some instances, adistal tip 240 of thespine member 134 can include a tapered arcuate end. In other instances, thedistal tip 240 can be bulbous or mushroom-shaped. In some instances, thespine member 134 can have a square-shaped cross-sectional profile; however, it will be appreciated that other cross-sectional profiles are possible (e.g., semi-circular, circular, rectangular, etc.). - In some instances, the
distal end portion 236 of thespine member 134 can extend at an angle A relative to a longitudinal plane P of theproximal end portion 234. In one example, the angle A can be about 10° to about 45°, depending upon the craniofacial anatomy of the subject. - The
spine member 134 can have a rigid, semi-rigid, or flexible configuration. Thespine member 134 can be made from one or combination of rigid, semi-rigid, or flexible materials, such as metals, metal alloys, and polymers or plastics. In some instances, all or only a portion of thespine member 134 can be malleable. For example, only thedistal end portion 236 of thespine member 134 can be malleable. In another example, thespine member 134 can be made of a malleable metal that supports thedouble barrel sheath 136 and the integral stimulation lead 22 from buckling when longitudinal or lateral forces are encountered. The malleability allows a physician to conform the shape of the neurostimulator 18 (e.g., the integral stimulation lead 22) to correspond to a patient's anatomy and thereby aid with implantation. Malleability in some cases is not required; thus, aspine member 134 made from a non-malleable material, such as plastic can also serve the intended function. - In another aspect, the
delivery tool 124 includes a double barrel sheath 136 (FIGS. 15A-C ) that is connected to thespine member 134. Thedouble barrel sheath 136 comprises afirst barrel 242 and asecond barrel 244. Afirst lumen 246 and asecond lumen 248 extend through the first andsecond barrels FIG. 15B , thesecond lumen 248 can have a rectangular cross-sectional profile and be shaped and dimensioned to receive all or only a portion of thespine member 134. Thefirst lumen 246 can have a circular cross-sectional profile and be shaped and dimensioned to partially receive theintegral stimulation lead 22 of theneurostimulator 18. Afirst end 250 of thedouble barrel sheath 136 is securely connected to thetrunk member 132 so that thecentral lumen 182 is in fluid communication with thefirst lumen 246. Thedouble barrel sheath 136 can be securely connected to thetrunk member 132 by any one or combination of attachment mechanisms, such as adhesives, pins, staples, etc. - In some instances, the
double barrel sheath 136 can be made of a semi-flexible material (or materials). In one example, thedouble barrel sheath 136 can be formed from a plastic or polymer, such as polytetrafluoroethylene. In other instances, thedouble barrel sheath 136 can be formed from a flexible material having a thickness of about 0.04 inches to about 0.001 inches. - In some instances, the
first barrel 242 of thesheath 136 has a splittable configuration to allow for removal or deployment of theintegral stimulation lead 22 of the neurostimulator 18 from the sheath with minimal load on the integral stimulation lead. A partial section of thefirst barrel 242 can include aseam 252 adapted to permit egress of thestimulation lead 22 from thefirst lumen 246 during deployment of theneurostimulator 18. Theseam 252 can extend from asecond end 254 of thesheath 136 to anopening 256, which is located at or about the midpoint of thefirst barrel 242. In some instances, the distance between thesecond end 254 and theopening 256 can be equal to, or about equal to, the length of thestimulation lead 22. Theseam 252 allows for removal or deployment of theintegral stimulation lead 22 of the neurostimulator 18 from thesheath 136 with minimal load on the integral stimulation lead. Undesirable loading on theintegral stimulation lead 22 can cause migration of the lead away from the desired implant location during withdrawal of thedelivery tool 124. Advantageously, only theseam 252 of thesheath 136 is parted during deployment of theneurostimulator 18, which reduces the load on theintegral stimulation lead 22. - Another aspect of the present disclosure is illustrated in
FIG. 16 and includes a navigation-assistedmethod 258 for deploying aneurostimulator 18 in close proximity to aSPG 10 of a subject. Themethod 258 can generally include the steps of: loading aneurostimulator 18 onto a delivery tool 124 (Step 260); advancing the delivery tool to a PPF 14 (Step 262); deploying an integrallead ejector 172 of the delivery tool (Step 264); and withdrawing the delivery tool from the subject (Step 266). In one example of themethod 258, thedelivery tool 124 is configured as shown inFIG. 10 and described above, and theneurostimulator 18 is configured as shown inFIG. 2 and described in the '641 patent. Steps 262-266 of themethod 258 can be performed using a commercially available navigation system, such as the KICK or CURVE systems (BRAINLAB, Westchester, Ill.), the FUSION ENT navigation system (Medtronic, Minneapolis, Minn.), or the NAV3 Navigation Platform (Stryker, Kalamazoo, Mich.). - Either prior to, contemporaneous with, or following
Step 260, a delivery path can be surgically formed in the subject as disclosed in the '480 application. Loading of theneurostimulator 18 onto thedelivery tool 124 is illustrated inFIGS. 17A-C . To do so, theneurostimulator 18 is first brought into close proximity with thehub portion 130 of thedelivery tool 124. Theneurostimulator 18 is then angled slight downward toward thedouble barrel sheath 136 of thedelivery tool 124 until a distal portion of theintegral stimulator lead 22 is introduced or inserted into theopening 256 of the sheath (FIG. 17A ). Next, theneurostimulator 18 is progressively advanced in a distal direction until a portion of theneurostimulator body 20 is in flush contact with thelower surface 206 of the hub portion 130 (FIG. 17B ). As shown inFIG. 17C , theneurostimulator 18 is then advanced towards thehandle 126 of thedelivery tool 124 until theneurostimulator body 20 snugly engages thetangs 212 and theintegral fixation apparatus 26 engages thesurface 218 of thehub portion 130, thereby providing a retention force to keep the neurostimulator securely mated with the delivery tool during implantation. - To form the delivery path, a gingival-buccal insertion site in a similar or identical manner as disclosed in the '258 application. In one example, a #10 scalpel blade (not shown) can be used to make an incision in a horizontal manner between the second and third molars (not shown). Next, a first surgical tool (not shown) similar or identical to the one disclosed in the '480 application is inserted into the incision and subperiosteally. In some instances, the anatomy of the subject's skull, including the location and size of the
PPF 14 can be determined prior to insertion of the first surgical tool. After inserting the first surgical tool into the incision, the first surgical tool is urged in a posterior direction so that a first major surface of the surgical tool's distal portion traverses under thezygomatic bone 28 along themaxillary tuberosity 120. The first surgical tool is then advanced further until a distal dissecting tip thereof engages the junction formed by the posterior maxillary buttress (not shown) and thepterygoid plate 122, just inferior and lateral to thePPF 14. Advancement of the first surgical tool may naturally stop when the distal dissecting tip is correctly positioned at the junction formed by the posterior maxillary buttress and thepterygoid plate 122. The first surgical tool is then withdrawn, thereby creating a surgical access cavity (not shown). - After forming the delivery path, the delivery tool 124 (with the
neurostimulator 18 loaded thereon) can be advanced through the delivery path until thestimulation lead 22 of the neurostimulator is adjacent the PPF 14 (Step 262). AtStep 266, thehandle 126 of thedelivery tool 124 can be manipulated by, for example, sliding thesecond component 140 axially away from thefirst component 138. Thesecond component 140 can be sufficiently advanced (relative to the first component 138) to cause thelead ejector 172 of thedelivery tool 124 to advance through thecentral lumen 182, which causes thestimulation lead 22 to emerge from theseam 252 of thedouble barrel sheath 136 so that the stimulation lead is in close proximity to theSPG 10. - At
Step 266, thedelivery tool 124 can be withdrawn so that theneurostimulator 18 remains implanted in the subject as disclosed in the '641 patent. Following completion of the surgery, and with theneurostimulator 18 securely implanted within the subject, an electrical current from the neurostimulator can be applied to theSPG 10 to treat a medical condition (e.g., headache). - From the above description of the invention, those skilled in the art will perceive improvements, changes and modifications. Such improvements, changes and modifications within the skill of the art are intended to be covered by the appended claims. All patents, patent applications, and publication cited herein are incorporated by reference in their entirety.
Claims (19)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/373,698 US20170165482A1 (en) | 2015-12-09 | 2016-12-09 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
US16/736,004 US11478641B2 (en) | 2015-12-09 | 2020-01-07 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
US17/933,950 US20230111536A1 (en) | 2015-12-09 | 2022-09-21 | Surgical Tools and Methods for Delivering a Neurostimulator into the Pterygopalatine Fossa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562265086P | 2015-12-09 | 2015-12-09 | |
US15/373,698 US20170165482A1 (en) | 2015-12-09 | 2016-12-09 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/736,004 Continuation US11478641B2 (en) | 2015-12-09 | 2020-01-07 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170165482A1 true US20170165482A1 (en) | 2017-06-15 |
Family
ID=57589274
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/373,698 Abandoned US20170165482A1 (en) | 2015-12-09 | 2016-12-09 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
US16/736,004 Active 2038-01-08 US11478641B2 (en) | 2015-12-09 | 2020-01-07 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
US17/933,950 Pending US20230111536A1 (en) | 2015-12-09 | 2022-09-21 | Surgical Tools and Methods for Delivering a Neurostimulator into the Pterygopalatine Fossa |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/736,004 Active 2038-01-08 US11478641B2 (en) | 2015-12-09 | 2020-01-07 | Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa |
US17/933,950 Pending US20230111536A1 (en) | 2015-12-09 | 2022-09-21 | Surgical Tools and Methods for Delivering a Neurostimulator into the Pterygopalatine Fossa |
Country Status (3)
Country | Link |
---|---|
US (3) | US20170165482A1 (en) |
EP (2) | EP4201471A1 (en) |
WO (1) | WO2017100530A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230404619A1 (en) * | 2022-06-15 | 2023-12-21 | Capri Medical Limited | Method of percutaneously implanting a medical implant and a delivery device for percutaneous delivery of a medical implant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120290057A1 (en) * | 2009-01-16 | 2012-11-15 | Carl Lance Boling | Apparatus and method for delivering a neurostimulator into the pterygopalatine fossa |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062470A2 (en) * | 2003-01-03 | 2004-07-29 | Advanced Neuromodulation Systems, Inc. | System and method for stimulation of a person’s brain stem |
US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
ES2540127T3 (en) | 2009-01-16 | 2015-07-08 | The Cleveland Clinic Foundation | Surgical guide for a pterygopalatine fossa therapy device |
US9220524B2 (en) * | 2009-01-16 | 2015-12-29 | The Cleveland Clinic Foundation | Surgical tools to facilitate delivery of a neurostimulator into the pterygopalatine fossa |
US8417353B2 (en) * | 2009-04-29 | 2013-04-09 | Medtronic, Inc. | Method and apparatus for securing an electrode |
-
2016
- 2016-12-09 EP EP22208433.7A patent/EP4201471A1/en not_active Withdrawn
- 2016-12-09 US US15/373,698 patent/US20170165482A1/en not_active Abandoned
- 2016-12-09 WO PCT/US2016/065757 patent/WO2017100530A1/en active Application Filing
- 2016-12-09 EP EP16816155.2A patent/EP3386583B1/en active Active
-
2020
- 2020-01-07 US US16/736,004 patent/US11478641B2/en active Active
-
2022
- 2022-09-21 US US17/933,950 patent/US20230111536A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120290057A1 (en) * | 2009-01-16 | 2012-11-15 | Carl Lance Boling | Apparatus and method for delivering a neurostimulator into the pterygopalatine fossa |
Also Published As
Publication number | Publication date |
---|---|
US20230111536A1 (en) | 2023-04-13 |
EP4201471A1 (en) | 2023-06-28 |
EP3386583A1 (en) | 2018-10-17 |
EP3386583B1 (en) | 2022-11-23 |
WO2017100530A1 (en) | 2017-06-15 |
US20200197697A1 (en) | 2020-06-25 |
US11478641B2 (en) | 2022-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9456836B2 (en) | Apparatus and method for delivering a neurostimulator into the pterygopalatine fossa | |
US10098662B2 (en) | Surgical tools to facilitate delivery of a neurostimulator into the pterygopalatine fossa | |
US10322279B2 (en) | Surgical guide and method for guiding a therapy delivery device into the pterygopalatine fossa | |
USRE46341E1 (en) | Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions | |
US8870773B2 (en) | Ultrasound-guided delivery of a therapy delivery device to a nerve target | |
US20090012577A1 (en) | Appartus and method for treating headache and/or facial pain | |
US20240198103A1 (en) | System, Method, and Apparatus for Neurostimulation | |
US20230111536A1 (en) | Surgical Tools and Methods for Delivering a Neurostimulator into the Pterygopalatine Fossa | |
US20160270817A1 (en) | Surgical guidance tool to facilitate delivery of a neurostimulator into a pterygopalatine fossa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |
|
AS | Assignment |
Owner name: AUTONOMIC TECHNOLOGIES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUHRS, TOM;CHENG, ALAN;POWELL, RYAN;AND OTHERS;SIGNING DATES FROM 20091006 TO 20160817;REEL/FRAME:056031/0106 |
|
AS | Assignment |
Owner name: AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AUTONOMIC TECHNOLOGIES, INC.;REEL/FRAME:056742/0465 Effective date: 20190410 Owner name: UNITY HA LLC, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC;REEL/FRAME:056742/0596 Effective date: 20191220 |
|
AS | Assignment |
Owner name: REALEVE, LLC, FLORIDA Free format text: CHANGE OF NAME;ASSIGNOR:UNITY HA LLC;REEL/FRAME:066403/0526 Effective date: 20210812 |